EBV VZV AdV Products for
IA/AB infectious disease
couv_cata_2012_V22_ang.indd 1 9/12/11 11:19:23 TABLEOFCONTENTS 1 3 4 5 6 7 8 9 9 9 30 32 34 11 11 11 11 14 14 14 14 15 15 15 15 16 16 16 16 17 17 17 20 21 22 23 24 25 26 27 10 12 13 18 29 38 - 41 42 - 45 ……………………………………………………………………………… ………………………… ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………………………………………………… ……………………………………………………………………………………… 71-020 71-106 71-100 71-101 71-105 71-103 68-008 68-009 68-020 71-004 71-005 71-010 71-012 71-007 71-008 71-009 71-006 71-300 68-006 67-012 67-090 67-050 67-080 67-130 67-065 67-025 69-100 69-003 69-010 69-002 69-004 69-013 69-005 69-011 71-015 71-016 71-017 …………………………………………………… …………… ………………… 19-002 & 19-0028 ……………………… ……………………… ………………………… ………………………………………………………………… ………………………………… …………………………… ……………………………… ……………………………… …………………………………………………………………………… ………………………………………………………………………………… …………………………………………………………………………………… …………………………………………… ……………………………………………… ………………………………………………… …………………………………………………………………………………… …………………………………………………… ts 2009 r-gene™ 1 n (Respiratory M.W.S. r-gene™) N …………………………………………………………… …………………………………………………………… 1 ……………………………………………………………… ……………………………………………………………… r-gene™ …………………………………………………………………………………………………………………………………… ………………………………………………………………… te ………………………………………………………………………………………………………………………………………… …………………………………………………………………… ………………………………………………………………………………………………………………………………………… ……………………………………………………………………………………………………………………………………………… ……………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………… ROBES n ……………………………………………………………………………………………………………………………………………………………………………………………………………………………… …………………………………………………………………………… NTIBODIES r-gene™ &P o ……………………………………………………………………………………………………………………………………………………………… Group & H A ………………………………………………………………………………… R-gene™ - Real-time PCR Complete kit c …………………………………………………………………………………… (M) YSTEM A EAGENTS f RIMERS S ………………………………………………………………………… ITS ITS R P K K ………………………………………………………………………………………………………………………………………
o ELL W ONOCLONAL ITS
M K Alphabetical Index Herpes Virus Antibodies Product Line BK Virus r-gene™Adenovirus r-gene™Parechovirus r-gene™ RSV A/B r-gene™hMPV A/B r-gene™Bocavirus r-gene™Influenza A/B r-gene™ CELL ControlDICO r-gene™ AmpliDICO r-gene™ ExtraRICO r-gene™ ExtraColour r-gene™ CompensationQuanti r-gene™ HHV8Bocavirus QS r-gene™ r-gene™CMV positive Clear QC control panel Hybridowell™ UniversalHerpes ConsensusHybridowell™ Generic HerpesEnterovirus Identification ConsensusJC/BK Consensus Adenovirus ConsensusChlamylege ENTEROVIRUS R-gene™ - Real-time PCR Complete kit CMV HHV6,7,8CMV R-gene™ R-gene™ -ADENOVIRUS - Quantification Quantification R-gene™EBV Complete R-gene™ - Complete Quantification kitHSV1 - kit Quantification HSV2 CompleteBK VZV Virus R-gene™ Complete kit R-gene™ - kit Quantification - Quantification Complete Complete kit kit HSV2 r-gene™ VZV r-gene™ JC Virus r-gene™ Product List by Catalog Number CINAkit Respiratory Virus Antibodies Product Line Principle of End-Point PCR Molecular Biology kits Bordetella parapertussis Influenza Quanti FluA QS r-gene™ HSV1 r-gene™ BORDETELLA Principle of real-time PCR R-gene™ kits le PTIMIZED ULTI NCILLARY OMPLETE OMPLETE
C C A O
M b
PTIMIZED OMPLETE Ta
PRODUCTLIST&INDEX O
IMMUNOLOGY End-point PCR Real-time PCR MOLECULARBIOLOGY C Real-time PCR R-gene™ kits
BK VIRUS ref.: 69-013B
REAL-TIMEPCR BORDETELLA ref.: 69-011B ENTEROVIRUS ref.: 69-005B HSV1 HSV2 VZV ref.: 69-004B EBV ref.: 69-002B ADENOVIRUS ref.: 69-010B CMV ref.: 69-003B CMV HHV6,7,8 ref.: 69-100B
Argene manufactures its reagents in compliance with cGMP and ISO 13485 for optimal product quality and consistent results. Argene has entered into a broad license agreement with F. Hoffman-La Roche Ltd and Roche Molecular Systems, Inc, covering real-time PCR Technology for the detection of human pathogens. Therefore the purchase of these products grants the purchaser rights under certain Roche patents (among others under the so-called 5’ Nuclease Detection patents and Chemically-Modified Hot Start Enzymes patents) to use them solely for human in vitro diagnostic testing services. No general patent or other license of any kind other than this specific right of use from purchase is granted hereby by Argene. For in vitro diagnostic use, CE marking in Europe - Please inquire. USA: For research use only. Not for use in diagnostic procedures.
2 REAL-TIMEPCR 3 3 +
W0
kits virus the for Control Negative 0 nm Amplification + Extraction of CT 53
™ T[CW0] [IC CT CT [IC W0] CT [IC W0] 560 nm ≤ EXTRACTED WO + IC and does not contain inhibitory agents of amplification. The sample is correctly extracted CT [ICsample] Sample interpretation CT [IC Sample] IC RESULTS EXTRACTION INTERPRETATION 0 nm SC control 53 Sensitivity Real-Time AMPLIFICATION QS 0 nm
QS4
53 T[CSample] [IC CT
* 560 nm To ia odi sample in load viral of CT 0 nm 0 nm QS3 53 53 for imported standard curve. 0 nm QS2 EXTRACTED SAMPLE + IC 53 QS3 Virus standard curve sample READY-TO-USEPREMIX Water 0 nm Quantification Standard Sensitivity Control Crossing Threshold Internal Control
QS1
53
Use only
* GLOSSARY: IC = W0 = CT = QS = SC = Principle of the quantification using Wavelength Reading Distribution inready-to-use the premix Principle of real-time PCR R-gene REAL-TIMEPCR i ( kit i ( kit eut r sflfrtedansso rmr neto n iu eciaina ela o the for as well as reactivation virus kit. and the infection with primary therapy. provided of patient all diagnosis of the control, management for extraction useful an are including Results controls, different with validated ag fpout,tesml nlsscnb iutnosyrnfrteohrvrss CMV viruses: other the for run the simultaneously on the be PCR within can real-time program analysis by amplification sample been detected general the have and with a manual) products, amplified to and of then Thanks is range (automatic platforms. DNA systems available Extracted purification kit. common DNA the and with specimen validated of types Several srfinl n opee the complete, and User-friendly eeto fHV7adHV8b eltm C fe ia N xrcin obndwith Combined extraction. DNA viral after PCR real-time by r-gene™ HHV-8 QS and HHV8 HHV-7 of detection M H678R- HHV6,7,8 CMV R-gene HHV6,7,8 CMV H- otlkl nrae h eodr M netosb rcs fcosratvto.We rmr neto cus H- salso is lymphoproliferative HHV-6 with occurs, associated infection is primary the and HHV-8 When HHV-6 on lymphomas. HHV-6. hepatitis. reactivation. some as depends and cross and way of same disease lymphadenopathy hosts). infection the process Castleman syndroma, of fragile acts a sarcoma, The HHV-7 as a mononucleosic HHV-6 by severity Kaposi patients. patients. known for as establish infections The immunocompromised immunocompromised such HHV-8 commonly CMV responsible in in diseases and are mortality secondary be infections immunosuppression. during high HHV-7 the to opportunistic patients an with occurs HHV-6, in increases suspected cases CMV, of transplant involved commonly extreme likely be signs. organ case in most 100%, infection to and and HHV-7 clinical in to likely primary pneumopathy rare very patients 50% diseases, The reactivate also and neurological AIDS between is may with pathologies. benign (e.g. (range associated of to virus host is range lead seroprevalency CMV the the wide may high of a Often blood by status for in infection. immune characterized responsible dissemination are dormant are viral HHV-8 and lifelong The and site) HHV-7 childhood. geographical HHV-6, young CMV, the on viruses. depending DNA are Herpesviruses R-gene HHV6,7,8 CMV D S FOR USE S N K N R R C D L S G T P D N A N O I T C E T E 4 MTOF IMIT ECHNOLOGY TATUS EPORTING ESULT PECIMEN THE OF RINCIPLE IT ONTROLS YNAMIC ECESSARY OF UMBER ENE e. 69-004 ref.: e. 69-013 ref.: M H678R-gene™ HHV6,7,8 CMV M R-gene™ CMV S TORAGE T W ARGET • • D ITHIN R M H678Rgn™-Qatfcto OPEEkit COMPLETE Quantification - R-gene™ HHV6,7,8 CMV M H678Rgn™-Qatfcto kit Quantification - R-gene™ HHV6,7,8 CMV ETECTION I NEOF ANGE U E NCLUDED eltm C o M n H- uniiain H- n H- detection. HHV-8 and HHV-7 quantification, HHV-6 and CMV for PCR Real-time T QUIPMENT NITS ESTS n dnvrswith Adenovirus and ) ,EVwith EBV ), T ( i ( kit EST e. 68-008 ref.: Q Q e. 69-003 ref.: UANTIFICATION TION O I AT C I F I T N A U B R-gene™ EBV i sdsge omauetevrlla fCV H- n the and HHV-6 CMV, of load viral the measure to designed is kit ,CVHV,, -ee i nbe H- quantification. HHV-8 enables kit R-gene™ HHV6,7,8 CMV ), M H678R-gene™ HHV6,7,8 CMV E N E G ,HV1 S- n Z with VZV and HSV-2 HSV-1, ), DNVRSR-gene™ ADENOVIRUS ™ ( C e. 69-002 ref.: H-:<3C 3 < HHV-6: G S A +2°C/+8°C H-:U7G U57 HHV-6: USA: F E -18°C/-22°C T 140 N E 15 H. 1 I U C 1 CMV: W G CMV: R G H-:1C 1 HHV-8: ™ HBTO AND NHIBITION OR ERUM EAL XTRACTION E T E L P M O TO P MPLIFICATION OF UMBER ENOMIC ENOMIC HOLE uniiainAssay Quantification - I -T N FOR U , ESTS 10 IME V B ENE ITRO LOOD R RINE 7 I D OPY ESEARCH . ETFCTO OF DENTIFICATION C.5 N 5’ PCR. XTRACTION : C TCINAND ETECTION V C OPY i ssial o n laboratory. any for suitable is kit ,BVwith BKV ), FOR OPIES IRAL A,B BAL, , D /PCR. K DN O PP FOR ODING A - : P , FOR OPIES E IAGNOSTIC T I ENE /PCR. i ( kit QIA - M - N E DNA - S - V - L - N - - M - QIA - V - R - Z A EZ1 - XTRACTION R LASMA C / U M EF R S1HV Z R-gene™ VZV HSV2 HSV1 M OPIES IGHT H-:U2G U42 HHV-7: ; RATK ERSANT TRATAGENE OTOR K ERSANT SE 2000 e. 69-010 ref.: PPLIED /PCR. UCLI EF AG AG :6-0 DAE (DNA 67-000 .: L. UCLEASE S :6-0B(Q 69-100B .: O IOPSIES CUBE AMP E NOT TEP AP NA P NA S,A CSF, , C NLY S / -G KVrsR-gene™ Virus BK VNE AND DVANCED YCLER M NGINE Q ENS SP U N . B L QIA , C L3P UL83 N B DNA ENE SE ATFCTO OF UANTIFICATION ™ HHV-7 IOSYSTEMS C M PCR M PCR ONTROL URE URE OF . ™ ® OT EM CE , T ® (A ® ™ ECHNOLOGY . I EASY . .Rslsare Results ). NCLUDED O S MNIOTIC F . CS LC C BBOTT SYMPHONY OR AMPLE PTICON OMPACT R-gene™ LOOD ROTEIN OLECULAR OLECULAR AND S , MAG U RIGIN ARKING ENE YSTEM ™ SE UANTIFICATION ). ENSITIVITY Z A EZ1 . . XTRACTION . I H-:OF6G ORF26 HHV-8: ; ® HHV-8. F M N . ™ ® , LUID D N KIT INI T ® I- (R P(Q SP (B IAGNOSTIC AQ CYCLER CMV S S (R DVANCED S , H-:<16C 156 < HHV-6: M:5 C 50 CMV: H-:<4 C 40 < HHV-8: OCHE IOMÉRIEUX YSTEM YSTEM E M OCHE C UROPE AMPLES AN (Q ONTROL K IAGEN AND IT XR DX , ® RDC INFORMATION PRODUCT D K IAGEN A , D(S AD (S SP . P D IAGNOSTICS IT ROCEDURES L(Q XL P - IAGNOSTICS ). HHV-6. ALBEWT THE WITH VAILABLE ). C ) ,N OPIES . MN FROM OMING ). EAL LEASE IEMENS 69-100 IEMENS 4 et 69-100 tests 140 4 et 69-100B tests 140 EGATIVE ENE IAGEN -T OPIES / M IME . OPIES . I ). L. NQUIRE ). ). ). ). / S M C YSTEM / M L. ONTROL G L. . C UTHRIE OMPLETE (B . IO 69-100 -R T EST AD K , IT ). ). REAL-TIMEPCR 5 ). ). IT , K AD . Retinitis, EST 3 T -R 69-003 transmission. IO . (B OMPLETE UTHRIE C . G in utero ONTROL YSTEM C S ). ). ). ). NQUIRE L. ). I . IME M / -T IAGEN 90tests 69-003 90tests 69-003B EGATIVE IEMENS 69-003 IEMENS LEASE EAL ). OMINGFROM OPIES ,N ). C ). VAILABLE WITH THE ). IAGNOSTICS -P XL(Q ROCEDURES IT IAGNOSTICS D P . family. The poorer the socio-economic SP(S AD(S ,A IAGEN K D PRODUCTINFORMATION ® ,DXR IT IAGEN K ONTROL (Q AN AMPLES UROPE C OCHE M E YSTEM YSTEM IOMÉRIEUX OCHE CMV: 50 C ,S DVANCED (R S S CMV. CYCLER AQ IAGNOSTIC (B SP(Q (R I- ® T INIKIT D LUID , ® ™ . kit N kit M F ® I . XTRACTION . . Herpesviridae EZ1 A ENSITIVITY ). UANTIFICATION SE ™ YSTEM ARKINGIN U MAG ,S OLECULAR OLECULAR ROTEIN LOOD OMPACT PTICON R-gene™ AMPLE OR SYMPHONY BBOTT C LCS . F MNIOTIC S O NCLUDED . EASY I . ECHNOLOGY ™ ® (A ® T ,CEM OT ® . OF URE URE ONTROL PCRM PCRM IOSYSTEMS ™ UANTIFICATIONOF SE ENE DNAB UL83 P C ,QIA L B .N U SP ENS Q NGINE M YCLER DVANCEDAND -G / S NLY C , CSF, A NAP NAP TEPNOT CUBE AMP IOPSIES O .: 69-003B (Q S UCLEASE L. .: 67-000 (DNA E AG AG EF UCLI PPLIED 2000 SE TRATAGENE ERSANTK ERSANTK OTOR IGHT OPIES M R EF M U / C LASMA R XTRACTION -R -V -QIA -M - -N -L -V -S -DNAE -M -QIA - EZ1 A IT IAGNOSTIC E HSV1 HSV2 VZV R-gene™ FOR ,P :-A ODINGFORPP K /PCR. D ,BAL,B IRAL OPIES FOR CMV HHV6,7,8 R-gene™ C kit is suitable for any laboratory. V ETECTIONAND C : XTRACTION PCR. 5’ N ESEARCH OPY D 7 RINE R LOOD . ITRO ENE B V IME 10 ,U FOR N ESTS -T I kit (ref.: 69-013 ) and Adenovirus with HOLE ENOMIC UMBEROF MPLIFICATION PTO OMPLETE XTRACTION EAL ERUM OR NHIBITIONAND F USA: I 1 H. 15 E N 90 T -18°C/-22°C E G R CMV: G W CMV: 1 C U +2°C/+8°C A S C CMV R-gene™ ). Results are validated with different controls, ™ ), HSV-1, HSV-2 and VZV with - Quantification Assay ref.: 69-010 BK Virus R-gene™ ™ kit ( UANTIFICATION UANTIFICATION Q Q ™ EST T ref.: 69-002 kit is designed to measure the viral load of CMV by real-time PCR after viral DNA ), CMV, HHV-6, HHV-7 and HHV-8 with ESTS kit ( NITS QUIPMENT T CMV genome quantification by real-time PCR. GENE NCLUDED E U ANGEOF I ETECTION CMV R-gene™ - Quantification COMPLETE kit CMV R-gene™ - Quantification kit R ITHIN D • • ARGET W T TORAGE
S ENE ECESSARY UMBEROF YNAMIC
IT ONTROLS TATUS EPORTING ESULT PECIMEN RINCIPLEOFTHE IMITOF ECHNOLOGY ETECTIONAND C L T G D N P N R R K S S USEFOR ref.: 69-004 including an extraction control,primary all infections provided and with virus the reactivation kit. as Results well are as useful for for the the management diagnosis of of patient therapy. (ref.: 69-100 ),ADENOVIRUS BKV R-gene™ with
( D Several types ofvalidated specimen with and the DNA kit.common purification Extracted available systems DNA platforms. (automatic isrange Thanks and then of to manual) products, amplified the a have and sampleEBV general been detected analysis amplification R-gene™ can by be program real-time simultaneously PCR within run for on the the the other viruses: EBV with observed before the era ofthe the second tri-therapies, leading in about clinicaldescribed 15 although manifestations. to the Multiple 35% incidence of typesCMV has the of R-gene™ not patients, neurological remains been the damage established. most Pneumopathy have common is been clinical exceptional. manifestation. The Peptic ulcers are
extraction. User friendly and complete, the CMVR- The human cytomegalovirus (HCMV) is a double stranded enveloped DNA virus of the
CMV R-gene CMV R-gene conditions, the higher theof prevalence (50 recurrent to secondary 100%). infections,with After during a the new chronic primary strain. or infection, Thein consequences HCMV transient healthy of remains immunosuppression, the subjects, in by HCMV it its infection reactivation may latent mainly of lead depend state to on the in the serious the endogenous cell damages host genome immunity in and of or immunosuppressed may the by subject patients be involved. reinfection and the Most cause in often the asymptomatic foetus or newborn child after The infection with HCMV afterInfection organ with or HCMV bone marrow isprophylactic allograft: observed, treatment HCMV between on is the the the 1st mainof average, and infectious in 4th agent reinfection month after two-thirds bone after and ofcomplications marrow the all less allograft graft. of recipients, and It than organ thrombo-leukopenia, is regardlesscomplication transplant. symptomatic of cytolitic 20% in of the two-thirds hepatitis, of a type of casesaddition, of gastric marrow the of transplant. infection graft. disorders primary reactivations. It with infection, It or occurs in HCMV Prolongedaggravates occurs 40% in cystitis. is the of fever in the a Chorioretinitis cases immunosuppression absence about may factor anddecreased is of 20% that be favours rare. by of triggers superinfections. the Interstitial all or 80% Infectionmanifestations only accelerates recipients occur pneumonitis with since at the and clinical HCMV is a rejection major its the during a manifestation stage or evolution, AIDS: of beginning major GVH of immunosuppression, without the (reaction characterised of the incidence treatment, by of an of is infection highly the average infections dangerous number graft or active with of (90% against CD4+ comprise HCMV anti-retroviral mortality). the T has lymphocytes In host). treatments under In 50/mm that addition, it provide at least partial immune restoration. Clinical REAL-TIMEPCR eut r aiae ihvroscnrl,icuiga xrcincnrl hc r l rvddwt h i.Rslsaevldfrthe for valid are Results kit. therapy. the patient with of provided management all the are for as which well control, as extraction infections an adenovirus including disseminated controls, early of various diagnosis with validated are Results with DNVRSR- ADENOVIRUS R-gene ADENOVIRUS ncs fannifciu iu.I hscs h ia odi o o ob eetdb elclueadrslsaenee ail.I is It rapidly. needed are results and culture cell by detected be The to low patient. with too each applicable is particularly for associated load is viral kinetics and highly-sensitive, the are viral is case the PCR this measurements real-time analyse In by virus. genome to load non-infectious viral recommended the a the of viral of detection case offers and cell be in Amplification Increased which death. can stem of with symptoms, methods. reliable risk virus more increased hematopoietic clinical validated The PCR be developing among can population. before prognosis quantitative and practice pediatric weeks Follow-up intervention. common the 2-3 for opportunity blood in a in especially Surveillance currently disease. detected recipients, disseminating is by (HSCT) a infection for samples transplant adenovirus suspected significative of a blood usually detection of is the case in since samples PCR, In blood by virus. from tested the affected DNA be of disease, should serotype specimens underlying blood and the adenovirus, age, on patient depending system, pneumonia, are as organ manifestations include recognized disseminated clinical and patients These increasingly meningoencephalitis disease. pancreatitis, immunocompromised been colitis, cystitis, have in hemorrhagic immunocompromisedhepatitis, adenoviruses manifestations among mortality years, Clinical and morbidity few patients. high throughout last with occur pathogens the viral and significant distribution Over worldwide year. a have the common, are infections Adenovirus R-gene ADENOVIRUS M R-gene™ CMV D hnst eea mlfcto rga ihteetr ag of range platforms. available entire common validated the the been on with have PCR manual) program real-time and by (automatic amplification detected systems and general purification amplified a DNA then to numerous is DNA and Thanks Extracted specimen kit. of the types with Many diagnostics. routine for nlzdwt h olwn te aaees S1 S2 Z with VZV HSV2, HSV1, parameters: other following the with analyzed dnvrssb eltm C fe ia N extraction. DNA viral after PCR real-time by Adenoviruses S FOR USE C K T L R R N S P N S G D D N A N O I T C E T E 6 MTOF IMIT ECHNOLOGY PECIMEN TATUS EPORTING ESULT THE OF RINCIPLE IT ONTROLS YNAMIC ECESSARY OF UMBER ENE S B R-gene™ EBV TORAGE T W ARGET • • D ITHIN R DNVRSRgn™-Qatfcto kit Quantification - R-gene™ ADENOVIRUS DNVRSRgn™-Qatfcto OPEEkit COMPLETE Quantification - R-gene™ ADENOVIRUS ETECTION I NEOF ANGE U E NCLUDED DNVRSgnm uniiainb eltm PCR. real-time by quantification genome ADENOVIRUS T QUIPMENT NITS ESTS i ( kit T EST ( e. 69-003B ref.: e. 69-002B). ref.: Q Q UANTIFICATION TION O I AT C I F I T N A U E N E G ,CV H-,HV7adHV8with HHV-8 and HHV-7 HHV-6, CMV, ), ™ ™ C +2°C/+8°C F E -18°C/-22°C T 90 N E 15 H. 1 I U W P H R G A N S:N USA: HBTO AND NHIBITION OR LASMA XTRACTION EAL E T E L P M O TO P MPLIFICATION ASAL EXON ME OF UMBER ENOMIC HOLE uniiainAssay Quantification - IN -T ESTS 5 IME ,W S V G B OT X ECRETION ITRO . LOOD 10 ENE D C.5 N 5’ PCR. XTRACTION HOLE : A TCINAND ETECTION V DNVRSR-gene™ ADENOVIRUS 6 FOR . IRAL VAILABLE D A - : K C FOR IAGNOSTIC E C 8 = OPIES T I B Z A EZ1 - - QIA - S - M - - V - L - B - - S - N - QIA - V - R - M - XTRACTION R LOOD C 0C 10 = XR DX M QIA EF R OPIES IGHT RATK ERSANT TRATAGENE MART OTOR K ERSANT IO 2000 PPLIED UCLI AG AG EF :6-0 DAE (DNA 67-000 .: / DNVRSR-gene™ ADENOVIRUS UCLEASE . OPIES R S M :6-1B(Q 69-010B .: S , AMP AMP CUBE OBOT E NOT TEP AP NA P NA L. EAL C S C R-gene™ -G / ™ VNE AND DVANCED YCLER TOOL M ENS SP Q OPIES YCLER U B /PCR. -T L QIA , N S DNA B DNA C ENE SE ™ ATFCTO OF UANTIFICATION IOSYSTEMS C M PCR M PCR URE URE M48 ONTROL OF IME ® EM CE , ® T (A A,U BAL, , S1HV Z R-gene™ VZV HSV2 HSV1 ® ™ ® . PR N /PCR. EASY ECHNOLOGY . I NCLUDED . . S CS LC C BBOTT M H678R-gene™ HHV6,7,8 CMV S SYMPHONY AMPLE OMPACT YSTEM (Q TOOL LOOD OLECULAR OLECULAR rdcs h apeaayi a esimultaneously be can analysis sample the products, MAG S , RIGIN ARKING saue-redyadcmlt i n hrfr ideal therefore and kit complete and user-friendly a is YSTEM ™ IAGEN ). UANTIFICATION Z A EZ1 RINE . ENSITIVITY . XTRACTION M M . (B ™ ® N KIT INI N KIT INI N , ® ). IO (R T (B P(Q SP AQ S S (R -R DVANCED A ASOPHARYNGEAL OCHE IOMÉRIEUX YSTEM YSTEM W i sdsge omauetevrlla of load viral the measure to designed is kit OCHE DENOVIRUSES E AD M ASAL HOLE (Q UROPE C (Q AN ). ONTROL K IAGEN IAGEN D IT IAGEN ® D(S AD (S SP RDC INFORMATION PRODUCT K A , D IAGNOSTICS S . B IT L(Q XL IAGNOSTICS ECRETION P - LOOD ). ). ALBEWT THE WITH VAILABLE ) ). ). ,N . IEMENS LEASE IEMENS i ( kit 69-010 . IAGEN i ( kit EGATIVE 0tss69-010B tests 90 0tss69-010 tests 90 0 C 200 = S PECIMEN e. 69-004B ref.: ). 6 C 261 = ). I e. 69-100B ref.: ). ). NQUIRE ). C B , ONTROL OPIES . IOPSIES C OPIES OMPLETE / M . ,CVwith CMV ), L. / CSF. , ,adEBV and ), M 69-010 L. K IT ). REAL-TIMEPCR 7 ). ) and IT ), CMV, K 69-002 . OMPLETE ). C . ref.: 69-013 ref.: 69-004 ONTROL C kit ( ). kit ( . ). ). ). NQUIRE ). I . IAGNOSTICS D IAGEN 90tests 69-002 90tests 69-002B ). ULTURE EGATIVE IEMENS ). C 69-002 IEMENS ). LEASE ,N AD ). ). OCHE VAILABLE WITH THE ELL ). IAGNOSTICS IAGEN -P XL(Q ROCEDURES -R IT IAGNOSTICS D P (R . SP(S AD(S ,A IO IAGEN K ,C D PRODUCTINFORMATION (Q ® IT IT IAGEN (B K ONTROL K (Q AN C UROPE OCHE ISSUE M E BK Virus R-gene™ YSTEM YSTEM IOMÉRIEUX OCHE CID DVANCED (R S S EBV. PINKIT ,T AQ IAGNOSTIC A (B SP(Q (R . YSTEM S ® T INIKIT D S ® ™ N M HSV1 HSV2 VZV R-gene™ I . XTRACTION . . IRUS EZ1 A ENSITIVITY kit is INASE ). IME UANTIFICATION IOPSIES SE ™ YSTEM V UCLEIC K ARKINGIN U -T MAG ,S N OLECULAR OLECULAR LOOD OMPACT ), BKV with AMPLE OR SYMPHONY EAL BBOTT C LCS LUTE . . F S NCLUDED . EASY I E . ® ECHNOLOGY IRAL ™ ® (A ® T V OT ,CEM IN ® ,BAL,B OF URE URE ONTROL L. PCRM PCRM IOSYSTEMS ™ HYMIDINE UANTIFICATIONOF ENE DNAB M SE C ,QIA M L B .N T / ,DXR YCLER U SP ENS Q URE M YCLER DVANCEDAND -G / C S P NLY C NAP NAP TEPNOT LASMA AMP AMP CUBE O EBV R-gene™ .: 69-002B (Q S UCLEASE OPIES ref.: 69-100 .: 67-000 (DNA E AG AG EF UCLI IGH PPLIED CYCLER 2000 SE ERSANTK ERSANTK MART OTOR TRATAGENE IGHT OPIES R EF M U range of products, the sample analysis can be simultaneously run for the C R kit ( XTRACTION -S -V - -QIA -R -M -QIA - EZ1 A -N -L -V -S -M -QIA -H -I- IT E ODINGFOR IAGNOSTIC FOR , CSF, P :-A K ). C D IRAL FOR V ETECTIONAND : XTRACTION PCR. 5’ N ESEARCH ), HSV-1, HSV-2 and VZV with D ENE R LOOD . /PCR. ITRO B R-gene™ V IME 5 000 000 C FOR ESTS -T IN OPIES HOLE ENOMIC MPLIFICATION UMBEROF PTO OMPLETE XTRACTION EAL ref.: 69-010 OR NHIBITIONAND A F USA: 90 T -18°C/-22°C E G R BXLF1 G W 4 C U I 1 H. 15 E N +2°C/+8°C C kit ( ref.: 69-003 kit ( ™ CMV HHV6,7,8 R-gene™ - Quantification Assay UANTIFICATION CMV R-gene™ ™ UANTIFICATION Q Q kit is designed to measure the viral load of EBV by real-time PCR ™ EST Adenovirus R-gene™ T ESTS NITS QUIPMENT T EBV genome quantification by real-time PCR. NCLUDED E U ANGEOF I GENE ETECTION EBV R-gene™ - Quantification COMPLETE kit EBV R-gene™ - Quantification kit R ITHIN D • • ARGET W T TORAGE
S EBV R-gene™ ENE ECESSARY UMBEROF YNAMIC
IT ONTROLS TATUS ESULT EPORTING PECIMEN RINCIPLEOFTHE IMITOF ECHNOLOGY ETECTIONAND C T G L N P N D R R S K S USEFOR Results are validateddiagnosis with of primary different infections controls, and including virus an reactivation extraction as control, well as all for provided the with management the of kit. patient Results therapy. are useful for the HHV-6, HHV-7 and HHV-8 with ADENOVIRUS with Thanks to a general amplification program within the Several typeshave of been specimen validatedreal-time and with PCR DNA the on the kit. purification common Extracted available systems DNA platforms. is (automatic then and amplified manual) and detected by suitable for any laboratory. other viruses: CMV with
D EBVR- The EBV is apathogenesis causative ofand agent several nasopharyngeal of cancerslymphoproliferation carcinoma. infectious such In as of mononucleosis.B immunosuppressed B Burkitt's lymphocytes cells. EBV individuals, lymphoma, multiply Indeed,context, is and EBV the Hodgkin's the also to may main measure lymphoma, involved subsequently lead characteristic of to the produce in of EBV a the EBV viral malignant is load lymphoma. to is make In very the this significant. Epstein-Barr (EBV)After virus a is prime anThis infection ubiquitous reactivation (transmission herpesvirus occurs by which saliva), with infects EBV a remains the replication latent major of in part EBV B of cells. in human the Periodically, population oropharynx EBV can (seroprevalence and reactivate does is in not 95%). healthy have individuals. any clinical signs.
EBV R-gene EBV R-gene after viral DNA extraction. User friendly and complete, the REAL-TIMEPCR S1HV Z R- VZV HSV2 HSV1 The R-gene VZV HSV2 R-gene HSV1 VZV HSV2 HSV1 rmr neto,tevrsprit nishs naltn tt n,asse ycrnco transient or chronic by assisted and, state latent a the in infections. human After recurrent eight host skin. give the are its to and There in reactivated membranes mucous be persists the can virus to immunosuppression, limited the generally infection, is infection primary primary The humans. in ytm aebe aiae nldn obndDARAetato i.Frti esn ti osbet efr iutnosyaDAanalysis DNA a simultaneously perform to possible is it with reason, this analysis For RNA kit. and extraction R-gene™ DNA/RNA VZV combined HSV2 a HSV1 including with validated been have systems hnst eea mlfcto rga ihnthe within program platforms. available amplification common general the a on to PCR real-time Thanks by detected and amplified r epnil,te r nutbefrsvr netoso h eta evu ytm(N)adcneia netos h iet banaresult a obtain to time The infections. congenital and (CNS) subjects. system immunocompetent inadequate. nervous viruses in are central these techniques infections which the for immunological of type thanks infections these infections The time, skin meningo-encephalitis for of severe benign long responsible in sensitivity the for a is the diagnosing increasingly unsuitable for which favourable for and subjects are revealed virus suitable more HSV-2 immunocompromised are they been is techniques in a responsible, has detection it encephalitis are has and but it with culture viruses, usually associated immunological techniques, HSV-2 conventional been VZV and detection Although had HSV-1 or genome virus both HSV-2 VZV to - viral disorders. traced by year to be neurological per caused can serious cases babies Encephalitis most 1/1,000,000 new-born the an untreated. to infections in VZV obtain 1/250,000 if encephalitis if or are to Neonatal HSV-2 fatal pathologies atypical there prognosis. HSV-1, essential be of these which therefore forms often of still treating is severe - can the it efficiently encephalitis and Among infections, HSV-1-induced in infection. severe adults, the severe worth in of In their diagnosis doses. These rapid proven appropriate and Usually identified. early at have infections. be and patients. antivirals to early such neonatal various virus immunocompetent prescribed forms years implicated clinical and in many the severe common allow For develop retinitis not nevertheless most do meningitis, can the infections viruses these encephalitis, are with (VZV) linked as infections Virus the Zoster benign, Varicella and redyadcmlt,the complete, and friendly iue:CVwith CMV viruses: D B R-gene™ EBV eut r aiae ihdfeetcnrl,icuiga xrcincnrl l rvddi h i.Rslsaeueu o h igoi fprimary of diagnosis the for useful are Results kit. therapy. the patient in of provided management all the control, for as extraction well an as including reactivation controls, virus different and infections with validated are Results S FOR USE S N K N R R C D L S G T P D N A N O I T C E T E 8 MTOF IMIT ECHNOLOGY TATUS EPORTING ESULT PECIMEN THE OF RINCIPLE IT ONTROLS YNAMIC ECESSARY OF UMBER ENE Herpesviridae S1HV Z R-gene™ VZV HSV2 HSV1 S TORAGE T W ARGET • • D ITHIN R S1HV Z -ee uniiainCMLT kit COMPLETE Quantification - R-gene™ VZV HSV2 HSV1 S1HV Z -ee uniiainkit Quantification - R-gene™ VZV HSV2 HSV1 ETECTION I NEOF ANGE U E NCLUDED S-,HV2adVVgnm uniiainb eltm PCR. real-time by quantification genome VZV and HSV-2 HSV-1, T i (ref.: kit QUIPMENT NITS ESTS M R-gene™ CMV r aiyo N iue hc r epnil o iesetu finfections of spectrum wide a for responsible are which viruses DNA of family a are T EST Herpesviridae Q 69-002 Q UANTIFICATION TION O I AT C I F I T N A U S1HV Z R-gene™ VZV HSV2 HSV1 ,BVwith BKV ), i sdsge omauetevrlla fHV1 S- n Z yra-iePRatrvrlDAetato.User extraction. DNA viral after PCR real-time by VZV and HSV-2 HSV-1, of load viral the measure to designed is kit i ( kit fwihHre ipe iu ye HV1 n (HSV-2) 2 and (HSV-1) 1 types Virus Simplex Herpes which of , E N E G e. 69-003 ref.: KVrsR-gene™ Virus BK ™ C Z:U VZV: U HSV-2: A +2°C/+8°C USA: F E -18°C/-22°C T 180 N E 15 H. 1 I U HSV-1: C 2 HSV-1: AND G CSF, G US7 HSV-1: R G S-:2C 2 HSV-2: Z:2C 2 VZV: S-:U2G VZV: US2 HSV-2: HBTO AND NHIBITION OR EAL XTRACTION E T E L P M O MPLIFICATION ME OF UMBER ENOMIC ,CV H-,HV7adHV8with HHV-8 and HHV-7 HHV-6, CMV, ), ™ O I -T N R-gene™ FOR GP i ssial o n aoaoy aiu ye fsmls uoai n aulextraction manual and automatic samples, of types Various laboratory. any for suitable is kit neoiu R-gene™ Enterovirus PHTHALMOLOGIC ESTS YNAECOLOGICAL IME V uniiainAssay Quantification - 9( 19 ITRO R TO P TO P TO P D ESEARCH . C.5 N 5’ PCR. XTRACTION : TCINAND ETECTION OPIES OPIES OPIES V i ( kit FOR ORF : IRAL D K 0 0 C 000 C 500 000 C 500 000 500 FOR E IAGNOSTIC ag fpout,tesml nlsscnb iutnosyrnfrteother the for run simultaneously be can analysis sample the products, of range ENE ENE e. 69-013 ref.: T I Z A EZ1 - QIA - M - N - - V - QIA - M - QIA - 17) XTRACTION /PCR. /PCR. /PCR. R C A U V EF R . . OPIES RATK ERSANT PPLIED RATK ERSANT SE UCLI EF AG AG :6-0 DAE (DNA 67-000 .: UCLEASE GENE S S S :6-0B(Q 69-004B .: O AMPLES CUBE AMP AMP MEARS E NOT TEP AP NA P NA NLY S / B VNE AND DVANCED M Q ENS U IOSYSTEMS . OPIES OPIES OPIES N . C M PCR L ( n dnvrswith Adenovirus and ) QIA , C M B DNA SE ATFCTO OF UANTIFICATION e. 69-005 ref.: C , C M PCR ONTROL URE URE OF B , ® IN OT EM CE , T ECHNOLOGY TNOSAND UTANEOUS E I EASY RONCHO / / / NCLUDED S F OLECULAR M M M LUTE CS LC C SYMPHONY OR AMPLE L. L. L. OMPACT ™ ™ LOOD OLECULAR L ; S , MAG U RIGIN ARKING V YSTEM SE UANTIFICATION IGHT ENSITIVITY Z A EZ1 IRUS -A . ntesm xrce ape xrce N sthen is DNA Extracted sample. extracted same the on ) XTRACTION M H678R-gene™ HHV6,7,8 CMV . I M S N LVEOLAR C ™ ® YSTEM D N KIT INI YCLER T ® S (R P(Q SP (B IAGNOSTIC AQ M I KIT PIN S-,HV2 VZV. HSV-2, HSV-1, S (R DVANCED OCHE IOMÉRIEUX YSTEM UCOUS E D(S AD ® M OCHE S ; DNVRSR-gene™ ADENOVIRUS C UROPE L AN (Q ONTROL K IQUID IAGEN MART IT ® (Q RDC INFORMATION PRODUCT D K IAGEN A , IEMENS P(S SP S . P D IAGNOSTICS IT MEARS ROCEDURES L(Q XL C IAGEN P - IAGNOSTICS ). BL,P (BAL), ALBEWT THE WITH VAILABLE YCLER ). ). ,N ). ;D R DX ); LEASE IEMENS 69-004 ,E 8 et 69-004 tests 180 8 et 69-004B tests 180 EGATIVE ® ). IAGEN R ; ARS . OTOR LASMA I i ( kit ). EAL NQUIRE ). ). N ). -T e. 69-100 ref.: OSE -G C IME ONTROL C , ENE i ( kit . T S ELL C HROAT YSTEM ™ OMPLETE e:69-010 ref: S ; C . TRATAGENE ULTURE (B 69-004 (ENT) ,EVwith EBV ), IO -R K . IT AD ). ). ® ). ; REAL-TIMEPCR ), ), 9 ), enables ref.: 69-004 ref.: 69-004 ref.: 69-004 kit (Argene, kit (Argene, ) for laboratories with a higher ) for laboratories with a higher ) for laboratories with a higher 71-016 71-017 71-015 kit (Argene, ref.: 69-004 ref.: 69-004 ref.: 69-004 kit ( kit ( kit ( 60reactions 2x450µL 71-016 60reactions 2x450µL 71-017 60reactions 2x450µL 71-015 HSV1 HSV2 VZV R-gene™ HSV1 HSV2 VZV R-gene™ For in vitro diagnostic use, CE marking in Europe - Please inquire. USA: For research use only. Not for use in diagnostic procedures. HSV1 HSV2 VZV R-gene™ HSV1 HSV2 VZV R-gene™ HSV1 HSV2 VZV R-gene™ HSV1 HSV2 VZV R-gene™ ™ ™ ™ ™ ™ ™ is an amplification premix which, in association with the is an amplification premix which, in association with the kit thus rounds off the tests offered by the kit thus rounds off the tests offered by the kit thus rounds off the tests offered by the is an amplification premix which, in association with the Real-time PCR amplification and detection of VZV. Real-time PCR amplification and detection of HSV-2. Real-time PCR amplification and detection of HSV-1. VZV r-gene™ HSV2 r-gene™ HSV1 r-gene™ • • •
HSV2 r-gene™ HSV1 r-gene™ VZV r-gene™ HSV1 r-gene™ HSV2 r-gene™ VZV r-gene™
USEFOR USEFOR USEFOR The
VZV r-gene VZV r-gene The
HSV2 r-gene HSV2 r-gene The
HSV1 r-gene HSV1 r-gene demand for HSV-1 analysis than HSV-2 and VZV. demand for HSV-2 analysis than HSV-1 and VZV. demand for VZV analysis than HSV-1 and HSV-2. The quantification of the VZV genome using real-time PCR methods. The The enables quantification of the HSV-1 genome using real-time PCR methods. enables quantification of the HSV-2 genome using real-time PCR methods. REAL-TIMEPCR redyadcmlt i n hrfr da o otn igotc.Tekthsbe lnclyvldtdo aytpso pcmnin specimen of types of many range on entire validated the platforms. clinically for amplification been program and amplification has manual) general kit and a The (automatic to diagnostics. systems Thanks routine purification for DNA ideal numerous therefore with and combination kit complete and friendly B with EBV N viruses: DNA iu.Vrlla esrmn n olwu nrnltasln ainswt K soitdnprptyealst dp the adapt to enables nephropathy associated drugs). BKV antiviral with with patients combination transplant in renal or in treatment The follow-up immunosuppressive and (only measurement treatment load Viral virus. KV BK place. in put to techniques specific major the the for remain seroprevalence search cytology high the urine the the with and blood to by PCR due both microscopy the in real-time obtained application is Electronic detected is Quantitative limited and be a antibodies. then diagnosis has infection stenosis, can only polyomavirus patients). virus tropism virological of diagnosis urethral the renal A transplant stage Serological patients), this emerging manifests samples. virus. kidney In and and urine (in transplant rejection. organ opportunistic and infections nephritis marrow of an tract cause the is bone interstitial major urinary general, nephritis (in and with In increases Interstitial cystitis nephropathy associated prevalence urothelium. this is hemorrhagic the tubulo-interstitial but as symptoms and 6%, and of kidney itself 0.3% the reactivation between immunosuppression. as The lies migrates of such virus and urine level the in latency, the asymptomatic Hereafter, virus of with is the BK childhood. of infects sites infection early during prevalence particularly primary Primary tract 100%). the papovaviridae, respiratory to of to the 60 family through the (seroprevalence to migrates belonging population human polyomavirus a virus, BK R-gene Virus BK eut r aiae ihaltencsaycnrl icuiga nenletato oto)poie ihtekit. the with provided control) extraction internal an (including controls necessary the all with validated are Results with KVrsR-gene Virus BK Q 10 S FOR USE L S D K R R N S P N G T C MTOF IMIT ECHNOLOGY PECIMEN TATUS EPORTING ESULT THE OF RINCIPLE TION O I AT C I F I T N A U IT ONTROLS YNAMIC ECESSARY OF UMBER ENE KVrsR-gene™ Virus BK S M R-gene™ CMV TORAGE T S U R I W ARGET • • D ITHIN R B R-gene™ EBV KVrsRgn™-Qatfcto kit Quantification - R-gene™ Virus BK KVrsRgn™-Qatfcto OPEEkit COMPLETE Quantification - R-gene™ Virus BK ETECTION I NEOF ANGE U E NCLUDED K eoeqatfcto yra-iePCR. real-time by quantification genome BKV T CVrsrgn™Primers/Probe r-gene™ Virus JC QUIPMENT NITS ESTS R- T EST E N E G Q i ( kit C UANTIFICATION i nbe h uniiaino Kvrsi eltm C fe ia N extraction. DNA viral after PCR real-time in virus BK of quantification the enables kit E T E L P M O e. 69-003B ref.: i ( kit ™ e. 69-002B ref.: ™ KVrsR-gene™ Virus BK K uniiainAssay Quantification - T I ,CV H-,HV7adHV8with HHV-8 and HHV-7 HHV-6, CMV, ), A +2°C/+8°C F E -18°C/-22°C T 90 N E 15 H. 1 I U C 2.6 W S R G 5C 65 S:N USA: HBTO AND NHIBITION OR MALL EAL XTRACTION ,HV1 S-,adVVwith VZV and HSV-2, HSV-1, ), TO P MPLIFICATION ME OF UMBER ENOMIC HOLE ( e. 71-004 ref.: IN -T ESTS OPIES OPIES ™ 10 IME A T V B OT ITRO LOOD . 11 D / NTIGEN C.5 N 5’ PCR. XTRACTION M /PCR. : A TCINAND ETECTION V i safs n estv ehdfrtedtcinadqatfcto fBK of quantification and detection the for method sensitive and fast a is kit C L. FOR IRAL VAILABLE D P , OPIES A - : FOR IAGNOSTIC E ,Aeoiu with Adenovirus ), S - QIA - M - L - N - - Z A EZ1 - V - S - V - QIA - R - M - XTRACTION LASMA R C (S XR DX R-gene™ EF R / OPIES IGHT RATK ERSANT TRATAGENE OTOR MART K ERSANT M PPLIED UCLI EF AG AG :6-0 DAE (DNA 67-000 .: T UCLEASE . L. A S :6-1B(Q 69-013B .: U , CUBE AMP E NOT TEP AP NA P NA G EAL C S C / -G ). VNE AND DVANCED YCLER M RINE Q ENS U YCLER B -T L QIA , C SE N B DNA ENE ATFCTO OF UANTIFICATION IOSYSTEMS C M PCR M PCR ONTROL URE URE is h apeaayi a esmlaeul u o l other all for run simultaneously be can analysis sample the kits, OF IME ® EM CE , T ® S ® ™ ECHNOLOGY ® AMPLES I EASY M NCLUDED S (R S CS LC C SYMPHONY (C (C AMPLE X YSTEM OMPACT LOOD OCHE 00,S 3000P, OLECULAR OLECULAR EPHEID ORBETT S , MAG RIGIN ARKING S1HV Z R-gene VZV HSV2 HSV1 dnvrsR-gene™ Adenovirus YSTEM ™ . UANTIFICATION ENSITIVITY Z A EZ1 . . XTRACTION . (B M H678R-gene™ HHV6,7,8 CMV M D ™ ® ). IAGNOSTICS N KIT INI IO R T ® (R P(Q SP (B AQ ESEARCH -R TRATAGENE BKV. S S (R DVANCED OCHE IOMÉRIEUX YSTEM YSTEM E AD M OCHE UROPE C AN (Q ). ONTROL K IAGEN IT ® RDC INFORMATION PRODUCT D K IAGEN ). A , D(S AD (S SP ). . D IAGNOSTICS IT L(Q XL P - IAGNOSTICS ® ). ALBEWT THE WITH VAILABLE ). ). ,N M LEASE ). IEMENS 69-013 X IEMENS EGATIVE 3005P. 0tss69-013B tests 90 0tss69-013 tests 90 IAGEN i ( kit KVrsR-gene™ Virus BK i ( kit I ). NQUIRE e. 69-004B). ref.: ). ). ). ). e. 69-010B ref.: C i ( kit ONTROL . C e. 69-100B ref.: OMPLETE . 69-013 sauser- a is ,CMV ), K IT ). ), REAL-TIMEPCR 11 71-010 71-004 71-005 71-020 real-time PCR products. Therefore 60tests 2x450µL 71-020 Argene 60reactions 2x450µL 71-010 60reactions 2x450µL 71-004 60reactions 2x450µL 71-005 Primers/Probes ™ ™ Primers/Probe Primers/Probe ™ ™ product is a premix designed to amplify Adenovirus using 5’ nuclease real-time assay Primers/Probes ™ ™ Primers/Probe Primers/Probe product is a premix designed to amplify BK Virus using 5’ nuclease real-time assay technology. The product is a premix designed to amplify JC virus using 5’ nuclease real-time assay technology. The amplification protocol is similar to other ™ ™ is designed for the real-time PCR detection of Parechoviruses on respiratory and cerebrospinal Parechovirus genome detection by real-time PCR. 5’ nuclease real-time PCR Adenovirus amplification and detection (7 species). Real-time PCR amplification and detection of BK Virus. Real-time PCR amplification and detection of JC Virus. Parechovirus r-gene™ Adenovirus r-gene™ Primers/Probes BK Virus r-gene™ Primers/Probe JC Virus r-gene™ Primers/Probe • • • •
Parechovirus r-gene™
USEFOR USEFOR USEFOR USEFOR Parechovirusinfections. can be tested simultaneously with other viruses involved in central nervous system and/or respiratory transcriptase isThe supplied along with an inhibition control and a positive control to validate the entire assay. Methods for DNA amplification using Polymerase Chain Reaction (PCR), RT-PCR process and 5' nuclease are covered by US patents issued to Human Parechovirusesidentified. (HPeV) Humanasymptomatic belong Parechoviruses infections.respiratory to However, the are illnesses,Parechovirus human Picornaviridae frequent encephalitis parechovirus pathogens r-gene™ family. and infections aseptic (seroprevalence Fourteen have meningitis. also types of been of described 95% Human has to be Parechoviruses been associated reported), with have serious usually been causing fluid samplesThe by using amplified the fragment 5' nuclease measures technology. 265 base pairs and is located in the 5'UTR region of the Parechovirus genome. Reverse Parechovirus r-gene Parechovirus r-gene Adenovirus r-gene™technology. The Primers/Probes targeted sequence corresponds to a fragment of 138 bp, located in the gene coding for the Hexon.
Adenovirus r-gene Adenovirus r-gene BK Virus r-gene™ Primers/Probe targeted sequence corresponds to a fragment of 197/198 bp located in the gene coding for the “Large T antigen”.
BK Virus r-gene BK Virus r-gene JC Virus r-gene™ Primers/Probe
JC Virus r-gene targeted sequence corresponds to a fragment of 197/198 bp located in the gene coding for the “Large T antigen”. JC Virus r-gene Hoffmann-La Roche. Neither anything in this publication nor purchase of these products from ARGENE should be construed as an authorization or implicit license to use these methods. REAL-TIMEPCR rvddwt h i.Rslsaeueu o h ai dniiaino all of identification rapid the for useful therapy. all are patient control, of Results extraction management an kit. the including and the real- controls, serotypes common with different respiratory most with various provided the with validated and samples, are specimens manual) of Results types and stool platforms. several (automatic PCR of on time samples, systems validated means purification by clinically CSF RNA been region, has on kit non-coding The cells. 5' culture amplification conserved or specimens highly PCR the of real-time amplification by 1.Crety h ehdo hiefrtedansso hs er-eigtsifcin stemlclrdansso CSF on diagnosis molecular the is cut infections to to 68 clinicians neuro-meningitis a examinations. sero-neutralisation enterovirus allowing a clinical enables these and by serotypes, PCR useless of A the necessary, and The real-time all diagnosis if (Coxsackievirus treatment of methods, virus). the followed, serotypes unnecessary PCR identification Simplex for culture certain off conventional sensitive Herpes cell for choice and than by or sensitivity of rapid faster isolation lacks virus method Much is worldwide. sometimes Mumps the samples. eradicated Enteroviruses method (e.g. being of Currently, currently traditional agents diagnosis 71). is this the disease infectious However, pathologies. for This other typing. Enterovirus neonatal method poliomyelitis. an or by anterior by standard in mucosa acute caused caused The infections cutaneous for meningitis common respiratory, those of responsible particular cardiac, criteria are from are with clinical Polioviruses and The associated discriminated October) meningitis. also be of to are cause May not Enteroviruses leading (from the can seasonally are mostly infection Enteroviruses occur adolescents. infections and Enterovirus children climates, temperate In nentoa omte nteTxnm fVrss 2005 Viruses. of Taxonomy the on Committee International NEOIU R- ENTEROVIRUS R-gene ENTEROVIRUS hn10srtpshv endsrbd fwih6 r urnl eonsdi h 05itrainlcasfcto ( More classification D). international and 2005 C the B, in A, recognised (Enterovirus currently families are 4 68 into which split of viruses, described, RNA been single-strand have are serotypes enteroviruses 100 family, than Picornaviridae the of Members R-gene ENTEROVIRUS D 12 S FOR USE D L K C R N R T S P S G N N O I T C E T E IMIT ECHNOLOGY TATUS EPORTING ESULT PECIMEN THE OF RINCIPLE IT ONTROLS YNAMIC ECESSARY OF UMBER ENE NEOIU R-gene™ ENTEROVIRUS S TORAGE O T W ARGET • • F D ITHIN R NEOIU -ee eltm C kit PCR Real-time - R-gene™ ENTEROVIRUS NEOIU -ee eltm C OPEEkit COMPLETE PCR Real-time - R-gene™ ENTEROVIRUS I NEOF ANGE ETECTION U E NCLUDED eltm C mlfcto n eeto fEnteroviruses. of detection and amplification PCR Real-time T QUIPMENT NITS ESTS C E T E L P M O T EST Q UANTIFICATION K E N E G i nbe h eei eeto fEnteroviruses of detection generic the enables kit T I ™ ™ A F E -18°C/-22°C T 90 Q E H. 2 I N/A (C 0.01 S CSF, N 5’ R R +2°C/+8°C HBTO AND NHIBITION OR EAL EAL XTRACTION MPLIFICATION UALITATIVE eltm C Assay PCR Real-time - IN -T -T ON ESTS IME IME XTRACTION TOOL V C OX ITRO . ODING C.5 N 5’ PCR. A PCR A13) : FOR R , T D EST A - : ). FOR ESPIRATORY IAGNOSTIC E R Z A EZ1 - QIA - V - S - S - L - N - - QIA - M - V - QIA - R - . XTRACTION EF R PIIAINAND MPLIFICATION S TO EGION XR DX :6-2 DARAE (DNA/RNA 67-020 .: R E NOT TEP IGHT RATK ERSANT MART TRATAGENE OTOR K ERSANT PPLIED UCLI EF AG 0(V)TCID (PV1) 10 UCLEASE :6-0B(R 69-005B .: CUBE AMP AMP AP NA EAL C . S C -G VNE AND DVANCED YCLER ENS ™ U YCLER S B -T SE M V RNA ENE C I PECIMEN (Q IOSYSTEMS NCLUDED C M PCR M PCR URE IME ONTROL ® IN EM CE , T . ® ™ ECHNOLOGY IAGEN ® E EASY . . . LUTE S C YSTEM OMPACT IRUS C , OLECULAR OLECULAR D MAG ,P . RIGIN ARKING ). TCINOF ETECTION 50 EAL V ™ ELL Z A EZ1 IRUS M / OSITIVE . M (B -T N KIT INI XTRACTION L. ™ ® C IME IO T ULTURE S (R (B AQ -R I KIT PIN S S DVANCED OCHE IOMÉRIEUX YSTEM YSTEM C K PCR C E AD M (Q ONTROL UROPE AN E ). . IAGEN NTEROVIRUSES K ® (Q RDC INFORMATION PRODUCT D IT D(S AD (S SP IT . A , IAGNOSTICS ). L(Q XL P - IAGEN N , ALBEWT THE WITH VAILABLE ). ). LEASE EGATIVE IEMENS 69-005 IEMENS ). 0tss69-005B tests 90 0tss69-005 tests 90 IAGEN . I ). NQUIRE ). ). C ). ONTROL . C OMPLETE 8 th . eoto the of report 69-005 K IT ). REAL-TIMEPCR ). 13 IT K ). 69-011 . OMPLETE C . IAGNOSTICS D ONTROL C ). NQUIRE ). I . OCHE 60tests60tests 69-011 69-011B (R . 69-011 EGATIVE ). LEASE ). VAILABLE WITH THE ,N ). IAGNOSTICS -P ROCEDURES IT IAGNOSTICS D P . ,A IAGEN K D PRODUCTINFORMATION ® . IT ORDETELLA ). K ). B (Q AN UROPE ONTROL OCHE M AD E C IOMÉRIEUX OCHE REPARATIONKIT (R IAGEN -R AQ P IAGNOSTIC (B (R ® T IO INIKIT D (Q ® ™ N M . (B I . XTRACTION . OSITIVE UANTIFICATION SE ™ YSTEM XPECTORATIONS ETECTIONOF ). ARKINGIN U ,P MAG E EMPLATE INIKIT D LOOD OMPACT YSTEM OR C LCS S . because it produces sensitive, specific and faster results . F NCLUDED . EASY I ® IAGEN ECHNOLOGY ™ ® T PCRT OT ,CEM ® ONTROL IME URE URE L. IOSYSTEMS (Q C ENE DNAB DNAM SE Bordetella -T M B .N YCLER U bacteria containing the IS481 sequence (traditionally found in ENS URE YCLER / -G C S P NLY C EAL NAP NAP . The bacteria TEPNOT AMP AMP CUBE O .: 69-011B (Q ™ S Bordetella UCLEASE .: 67-000 (DNA E AG AG EF SPIRATIONSAND UCLI IGH PPLIED SE MART OTOR IGHT R EF A U DXR ENOME MPLIFICATIONAND R XTRACTION . -R -QIA -QIA -M -H - -N -L -S -M -QIA G E IAGNOSTIC FOR Bordetella . :-A EST D FOR T : XTRACTION PCRA PCR. 5’ N ESEARCH R . ITRO EGION V IME IME ACTERIAL FOR ESTS -T -T IN Bordetella pertussis UALITATIVE MPLIFICATION ASOPHARYNGEAL XTRACTION EAL EAL - Real-time PCR Assay OR NHIBITIONAND N/A 1 H. 15 E N F USA: I Q 60 T -18°C/-22°C E R R IS481 R <10 B A +2°C/+8°C R-gene ™ ™ IT kit enables the detection of K GENE R-gene R-gene™ - Real-time PCR kit R-gene™ - Real-time PCR COMPLETE kit R- UANTIFICATION Q is generally diagnosed by cell culture. This technique is still the reference technique in all cases of non-vaccinated ) using real-time PCR on respiratory samples (nasopharyngeal aspiration and expectoration). EST R-gene™ T OMPLETE C ESTS NITS QUIPMENT T Real-time PCR amplification and detection of NCLUDED E U ANGEOF I ETECTION BORDETELLA BORDETELLA R ITHIN D • • ARGET W
T TORAGE
S
BORDETELLA ENE ECESSARY UMBEROF YNAMIC
IT ONTROLS TATUS ESULT EPORTING PECIMEN RINCIPLEOFTHE IMITOF ECHNOLOGY ETECTION D G S P N L R N C R K S T USEFOR D or incompletely vaccinatedbecause patients. it ispathogen. Diagnosis Real-time not by PCR possible serology is an to is effective also differentiate alternative used for between diagnosing but the presents vaccinal problems serological associated response with and the the vaccination response to an infection by the The than culture. Whooping cough isaffects a highly children contagious undermonths, childhood 5 because respiratory yearsantibodies they disease. old against do It and whooping mainly notthen cough may have lead do be not to any verydisease cross respiratory immunity may the serious complications placenta). be against incan fatal The (apnea infants the among disease and affect under newborn can illnessmorbidity bacterial infants 6 people (maternal have surinfections). under been 6 of Thismode months. reduced of the Whooping any by disease coughor 95%. has age. vaccination been However, boosting. observed In aadolescent It for change no to some well-vaccinated longer non-vaccinated in years occurs in infants. the from countries, the transmission child absence to of mortality child natural but and from adult or enter therespiratory body throughimpairments tract the that airways it (trachea causes and are attach due and to to the bronchi). pertussis the toxin mucosa that The is of released. the inflammatory upper and necrotic BORDETELLA Bordetella pertussis Bordetella pertussis Whooping cough is caused by the bacterium
BORDETELLA BORDETELLA Results are validated with different controls, including an extraction control, all provided in the kit. Several types ofdetected purification by systems real-time (automatic PCR and on manual) the have commonly been available validated platforms. with the kit. Extracted DNA is then amplified and REAL-TIMEPCR agtdsqecscrepn oafamn f7 p oae ntegn oigfrtennsrcua rti NS1. protein structural non the for coding gene the in located bp, 77 of fragment a to correspond sequences Targeted uhrzto ripii ies oueteemethods. these use to license implicit or authorization ofanL oh.Nihrayhn nti ulcto o ucaeo hs rdcsfo REEsol ecntuda an as construed be should ARGENE from products these of purchase nor publication this in anything Neither Roche. Hoffmann-La osbepeec fihbtr gnso amplification. of agents inhibitory of presence possible oaiu -ee Primers/Probe r-gene™ Bocavirus r-gene Bocavirus r-gene Bocavirus ehd o N mlfcto sn oyeaeCanRato PR,R-C rcs n 'nces r oee yU aet sudto issued patents US by covered are nuclease 5' and process RT-PCR (PCR), Reaction Chain Polymerase using amplification DNA for Methods parapertussis Bordetella parapertussis Bordetella parapertussis Bordetella h agtdsqec orsod oafamn f15b,lctdi h eecdn o arca protein. matricial a for coding gene the in located bp, 135 of fragment a to corresponds sequence targeted The Primers/Probes r-gene™ A/B hMPV r-gene A/B hMPV nucleoprotein. a for coding gene the in located bp, 185 of fragment a to corresponds sequence targeted The Primers/Probes r-gene™ A/B RSV r-gene A/B RSV r-gene A/B RSV parapertussis MVABr-gene A/B hMPV 14 S FOR USE FOR USE S FOR USE S FOR USE FOR USE • • • • odtlaparapertussis Bordetella oaiu -ee Primers/Probe r-gene™ Bocavirus MVABrgn™Primers/Probes r-gene™ A/B hMPV Primers/Probes r-gene™ A/B RSV ’nces eltm C oaiu mlfcto n detection. and amplification Bocavirus PCR real-time nuclease 5’ parapertussis Bordetella PCR real-time nuclease 5’ ’nces eltm TPRRVAadBapiiainaddetection. and amplification B and A RSV RT-PCR real-time nuclease 5’ ’nces eltm TPRhP n mlfcto n detection. and amplification B and A hMPV RT-PCR real-time nuclease 5’ sn h 'nces ehooy nitra oto hcs ntesm ue h fiinyo xrcinse n the and step extraction of efficiency the tube, same the in checks, control internal An technology. nuclease 5' the using , r-gene™ ™ ™ ™ rdc sapei eindt mlf S n sn ’nces eltm sa technology. assay real-time nuclease 5’ using B and A RSV amplify to designed premix a is product Primers/Probes rdc sapei eindt mlf MVAadBuig5 ulaera-ieasytechnology. assay real-time nuclease 5’ using B and A hMPV amplify to designed premix a is product rdc sapei eindt mlf oaiu sn ’nces eltm sa technology. assay real-time nuclease 5’ using Bocavirus amplify to designed premix a is product Primers/Probes Primers/Probe sarayt-s rmxotmzdfrtera-ieapiiaino S01rgo of region IS1001 of amplification real-time the for optimized premix ready-to-use a is r-gene™ xrcinadapiiaincontrol. amplification and extraction odtlaparapertussis Bordetella ™ ™ ™ r-gene Primers/Probes Primers/Probe Primers/Probes ™ r-gene mlfcto n detection. and amplification 0ratos2x40µ 71-012 µL 450 x 2 reactions 60 0ratos2x40µ 71-009 µL 450 x 2 reactions 60 0ratos2x40µ 71-008 µL 450 x 2 reactions 60 71-007 µL 450 x 2 reactions 60 ™ 71-012 71-009 71-007 71-008 o eerhueonly. use research For Bordetella REAL-TIMEPCR 1 N 1 15 68-006 in respiratory ); 1 N 68-006 1 71-300 71-006 ref.: 71-300 will allow to obtain relative 71-106 ™ premix ( ). r-gene™ 60tests 2x450µL 71-300 ™ 1 N ref.: 71-006 1 30 reactions 60reactions 2x450µL 71-006 100reactions 2x750µL 71-106 premix ( 2009 r-gene Quanti FluA QS r-gene™ Group & H and detection of Influenza A group viruses 1 ™ Primers/Probes 1 (M) N N 1 1 ™ determines the number of cells in the sample by using the quantification 2009 r-gene A/H ™ 1 Influenza A N ) in parallel with 1 2009 r-gene™ product is a premix designed to amplify Influenza A virus and Influenza A/H ™ Primers/Probes 1 N product is a premix designed to amplify Influenza A and B viruses using 5' nuclease 1 ™ 2009 virus using ™ ref.: 71-106 ( 1 CELL Control r-gene™ N 1 ) Group & H Influenza A/B r-gene™ Primers/Probes 2009 r-gene™ M 1 Group & H Group & H ( is a ready to use premix designed to validate results obtained by real-time amplification checking the N is designed to quantify the genome of the following Influenza viruses: 1 A (M) (M) A A Group & H CELL Control r-gene™ Quantification of cells in the sample. Amplification and detection of Influenza A and B viruses by real-time RT-PCR. Validation of the presence of cells in the sample by real-time PCR assays for DNA or RNA genomes. Quantification of Influenza A group viruses and/or novel 2009 Influenza A/H Typing of the novel 2009 Influenza by real-time RT-PCR. samples by real-time qPCR. (M) CELL Control r-gene™ Quanti FluA r-gene™ Influenza A/B r-gene™ Primers/Probes Influenza A • • • • - Swine-lineage Influenza A/H - Influenza A virus using
CELL Control r-gene™
USEFOR USEFOR USEFOR USEFOR USEFOR standards supplied with the kit. presence of cells in extracted samples. real-time assayfor technology. a Targeted matricial sequences protein. correspond to fragments of 233 and 146 bp, located in the M gene coding The use of quantification in copies of virus per cell. The
CELL Control r-gene CELL Control r-gene Quanti FluA QS r-gene™
Quanti FluA QS r-gene Quanti FluA QS r-gene Influenza 2009 virus usingin the 5' M nuclease gene real-time coding for assay a technology. matricial Targeted protein. sequence corresponds to a fragment of 233 bp, located
Influenza Influenza Influenza A/B r-gene™ Primers/Probes
Influenza A/B r-gene Influenza A/B r-gene REAL-TIMEPCR h nlsso eut bandwt h P rmxvldtsteetato rcs swl stepeec of presence the as well as process extraction the validates premix DP2 the sample. with the with in provided obtained also is agents extraction, results the through inhibitory sample of a as amplification processed analysis the (W0), conditions. water in grade The PCR standard control, DNA. distributed reference in A be target usual must the as to product performed Extracted then is step h fiinyo h xrcinpoeue(yi nldd n h osbepeec fihbtr gnsi h xrce product. extracted the in with agents inhibitory of provided presence possible (IC2) the and control included) (lysis procedure internal extraction The the of efficiency the aet sudt .Hfmn-aRceLde oh oeua ytm,Ic ete ntigi hspbiainnrprhs fthis of purchase nor publication this in anything Neither Inc. Systems, Molecular Roche et Ltd Roche Hoffmann-La F. to issued patents rdc rmAGN hudb osre sa uhrzto ripii ies oueteemethods. these use to license implicit or authorization an as construed be should ARGENE from product ehd o N mlfcto sn h ees rncito C rcs n/rte5'Nces eeto rcs r oee by covered are process Detection Nuclease ' 5 the and/or process PCR Transcription Reverse the using compensates correction The amplification reaction. DNA nm). for dual-colour (530-560 this fluorophores by Methods different caused 2 containing bleed-over capillary the single one corrects in file obtained results compensation analyse to colour software The r-gene™ 2.0 LightCycler© Compensation Colour r-gene Compensation COLOUR r-gene™ Extra DICO r-gene Extra DICO The r-gene Ampli DICO r-gene Ampli DICO eltm C 5 nuclease). (5’ PCR real-time h nlsso eut bandwt h P rmxvldtsteetato rcs swl stepeec of presence the as well as process extraction the validates premix RP1 the with with provided obtained also is extraction, results the through sample of a as processed analysis (W0), water grade The PCR control, RNA. reference A target the to xrce rdc utb itiue nthe conditions. in standard distributed in be usual must as product performed Extracted then is step h fiinyo h xrcinpoeue(yi nldd n h osbepeec fihbtr gnsi h xrce product. extracted the in with agents inhibitory of provided presence possible (IC1) the and Control included) (lysis procedure Internal extraction The the of efficiency the OORCmesto r-gene Compensation COLOUR r-gene™ Extra RICO r-gene Extra RICO r-gene Extra RICO r-gene Extra DICO h aawihrslsi igeadcmlt loecn y inlprLgtylr . channel. 2.0 LightCycler© per signal dye fluorescent complete and single a in r-gene™ results Compensation Colour which data the mlfcto niioyaet ntesample. the in agents inhibitory amplification 16 S FOR USE FOR USE FOR USE S FOR USE IOApir-gene™ Ampli DICO • • • • OORCmesto r-gene™ Compensation COLOUR r-gene™ Extra RICO r-gene™ Extra DICO r-gene™ Ampli DICO raino oorcmesto ie(3-6 mo LightCycler on nm (530-560 file compensation colour of Creation genomes. DNA on assays PCR real-time for control inhibition and Extraction PCR. real-time for premix control inhibition target DNA xrcinadihbto oto o eltm C saso N genomes. RNA on assays PCR real-time for control inhibition and Extraction hcsteetr eltm rcs rmetato oapiiain(’nuclease). (5’ amplification to extraction from process real-time entire the checks hcsteetr eltm rcs rmetato oapiiain(’nuclease). (5’ amplification to extraction from process real-time entire the checks sarayt-s rmxdsge ocnrltepeec fapiiainihbtr gnsin agents inhibitory amplification of presence the control to designed premix ready-to-use a is scmlatwt h full the with compliant is ™ ™ sasto ed-ouepeie eindt raeaclu opnainfl in file compensation colour a create to designed premixes ready-to-use 3 of set a is ™ IOEtar-gene™ Extra DICO IOEtar-gene™ Extra RICO IOEtar-gene™ Extra DICO IOEtar-gene™ Extra RICO ™ ™ reeR-gene™ Argene ™ ™ saddt h apepirt xrcin h extraction The extraction. to prior sample the to added is saddt h apepirt xrcin h extraction The extraction. to prior sample the to added is airto us3x6 L71-103 µL 60 x 3 runs calibration 2 rmx(P)adi h mlfcto rmxspecific premix amplification the in and (DP2) premix rmx(P)adi h mlfcto rmxspecific premix amplification the in and (RP1) premix range. 0 reactions 100 reactions 100 71-100 µL 750 x 2 reactions 100 ™ © 2.0). IOEtar-gene™ Extra DICO IOEtar-gene™ Extra RICO IOEtar-gene™. Extra DICO IOEtar-gene™. Extra RICO 71-101 71-100 71-103 71-105 o eerhueonly. use research For 71-105 71-101 controls controls REAL-TIMEPCR kit 17 68-008 Clear QC Panels undergo the same Bocavirus r-gene™ are manufactured to ( For research use only. 68-008 68-009 68-020 have been developed to includes several vials which validate the entire molecular 71-009 consists of 4 quantification CMV HHV6,7,8 R-gene™ Clear QC Panels Clear QC Panels Clear QC Panel Clear QC Panels Clear QC Panels 30 reactions 10reactions 100µL 68-009 ™ Quanti HHV8 r-gene™ ). 3vials Freezedried 3x1mL 68-020 ref.: 69-100 positive control ™ kit (Argene, ™ positive control ). consists of extracted DNA that should be amplified with reagent evaluate the performance and the robustness of different molecular assays. ™ is designed to quantify herpesvirus 8 genome. ref.: 69-100 CMV HHV6,7,8 R-gene™ Clear QC Panels are reference material for internal quality control of molecular virology assays. ). Quantitative or qualitative molecular virology. Research. Conventional and real-time PCR. Positive control for 5' nuclease real-time PCR Bocavirus amplification and detection. HHV-8 genome quantification range for real-time PCR application with (Argene, Bocavirus r-gene™ positive control CMV Clear QC Panel Quanti HHV8 r-gene™ • • • specifications by QCMD organisation (Quality Control for Molecular Diagnosis). Each
Bocavirus r-gene USEFOR USEFOR USEFOR USEFOR USEFOR been chosen to cover a wide spectrum corresponding to the usual values found in virology labs. The daily routine use of Primers/Probe standards (QS1,(R8) QS2, provided QS3, with the QS4) ranged from 5 000 copies/µL to 5 copies/µL to be amplified with the HHV-8 amplification premix corresponds to current laboratory quality control policy (e.g. Good Laboratory Practice). corresponds to standardised levels of concentrations (quantified in viral copies per mL). The different levels of virus concentration have Argene Methods for DNA amplification using Polymerase Chain Reaction (PCR), RT-PCR process and 5' nuclease are covered by US patents issued to Clear QC Panels
CMV Clear QC Panel CMV Clear QC Panel
Bocavirus r-gene™ Positive Control Bocavirus r-gene Quanti HHV8 r-gene™
Quanti HHV8 QS r-gene Quanti HHV8 QS r-gene testing process (conventional PCR or real-time PCR) whatever the amplified sequence may be. treatment as the clinical sample during the entire assay (from extraction to detection). Thus, monitor the performance ofresearch the approach, molecular testing process and for the detection of random or systematic errors in routine methods. In a Hoffmann-La Roche. Neither anything in this publication nor purchase of these products from ARGENE should be construed as an authorization or implicit license to use these methods. MULTI WELL SYSTEM r-gene™ eprtr ...r-gene M.W.S. Respiratory r-gene M.W.S. Respiratory 18 S FOR USE Negativecontrol (qualityPCRwater) Specificamplification premix ReverseTranscriptase (forRNAvirus) Positive control TaqMan technologyandcontain: nuclease 5’ use kits our All l u rmxsaeue redya hyaerayt s.Clrcdsalwaqikietfiaino rdcsadraet.A last, At reagents. and re-use. products for possibility of the identification and quick storage a easy allow for codes packaging Color polypropylene use. compact to a ready in are products they our as supply friendly we user are premixes our All r-gene™ doesnotrequire anyadditionalequipmentortraining. MWS solutions, multiplex others many Multi Unlike the with compatible are platforms PCR real-time available commonly All rapid more a choice. facilitate of method and the resistance patient-tailored is antibiotic to PCR potential real-time leading reduce diagnosis, pathogen, outbreaks, are a respiratory such control symptoms ensure with causal to Clinical help the possible pneumoniae. also identify only threatening will rapidly is life diagnosis to agents potentially essential to causative is infections the and detection tract of Adenovirus respiratory discrimination B), upper and and limiting A are similar (RSV self adults Virus and mild Syncytial children from Metapneumovirus, Respiratory in diseases human 3, ARI 4, type Parainfluenzavirus of and Enterovirus, causes 2 Bocavirus, major type pneumoniae, Coronavirus, The 1, as infections. such type pathogens respiratory viruses Other of Parainfluenza Rhinovirus. majority viruses, B vast Respiratory and the Lower A for and Influenza responsible media, are viruses otitis and acute Bacteria exacerbations, asthma pneumoniae. acute and brochiolitis, to lead young can are URTI distress respiratory fatal to a continue Respiratory developing Upper and for countries risk industrialized increased in at elderly. morbidities Populations the acute worldwide. and all persons illnesses of immunocompromised acute infants, 75% of estimated cause an leading for the be account (ARI) Infections Respiratory Acute OTNSO W r-gene™ MWS OF CONTENTS eeto n mlfcto frsiaoyptoesb eltm PCR. real-time by pathogens respiratory of amplification and Detection Chlamydophila pneumoniaeandLegionellapneumophila,alsoinfecttherespiratorytractcancausevarious Tract Infections(URTIs)suchasrhinitis,pharyngitis,andlaryngitisareamongthemostcommoninfectionsinchildren. ™ h eut r aiae ihpstv,ngtv n ellrcontrols cellular and negative positive, with kits. validated the with extraction. provided are after half results a and hour The one than less within pathogens MWS Respiratory The a of the specificity using the strategies and detection is sensitivity multiple it allowing Indeed, solution infections. multiplex respiratory modular of a diagnosis in challenges the DNA to (both response pathogens of Multi range Respiratory entire protocol the uniform for RNA). common a and is following program performed infectious the be of and can detection amplification duplex simultaneous The the diseases. respiratory for in involved kits agents complete PCR real-time Multi Respiratory ag fra-iePRkits PCR real-time of Range - in vitrodiagnosticmolecularmethods.Earlyandspecific ™ Well System(MWS)r-gene™ isabrandnewconceptof Well System(MWS)r-gene™ isaninnovativesolutionin Well Systemr-gene™ range. r-gene™ allowsthesimultaneousdetectionof35 71-04X Taqman® 5’nucleaseassay. Tract Infections(LRTI)suchasbronchitis, therapy. Arapidandaccurate
patient’s recovery. To
M
M M Mycoplasma
. .
WW
. S . MULTI WELL SYSTEM r-gene™ 19 ™ :
:
.
ENE S . r-gene
C EVELOPMENT
W W D /C
.: 71-046
. EGIONELLA . PNEUMOPHILA EF L ELL CONTROL PNEUMOPHILA HPRT1 G 71-04X EGIO L. NDER L ol M M U rrol ttr n on ™ : ee Co 1,2,3,4 en 2 m ontrol ve Co Co vve ve iv r-gene V:C ENE ENE ti iti O si C o 560 nm 560 nm H .: 71-045 R NG NG Positive Control Positive PPsiPo Pathogen 2 Pathoge EF V 229E, NL63, V/HPIV or Cell co or Cell control ARAINFLUENZA R HKU1, OC43 O O P C C H H ARAINFLUENZA P ™ : ROTEIN PCR : r-gene P ODING FOR PRODUCTINFORMATION IME ODING FOR AmplificationAmplification premix premix 15µL 15µL -T C 530530 nm nm 71-04X URFACE S .: 71-044 Pathogen 1 Pathogen 1 YTADHESINE EAL PNEUMONIAE ENE PNEUMONIAE EF C R YCO PNEUMO OMP2 C R ® C. M. /M P1 G YCOPLASMA PNEUMONIAE ENE EMBRAN HLAMYDOPHILA PNEUMONIAE G M HLA M C C AQMAN T ™ e ENES le : ATHOGENSBY : pl P ENE 560560 nm nm 15µL r-gene ™ G PPathogen 2 Pathogen 2 mmmpl r Cell control V VP1 G ATHOGENS O or or Cell control V 1,2,3,4 B P .: 71-043 OCAVIRUS ECHNOLOGY DENOVIRUS O EXON Sample Sa H AND EF T B H . V/ V A,B,C,D,E,F,G H . 10µL10µL D D A NS1 ESPIRATORY R NQUIRE ™ I UCLEASE ROCEDURES :B EGION P R ENE r-gene 5’ N A,B,C A LEASE . A,B,C,D C &EV: A Extraction Extraction -- Range Range of of real-time real-time PCR PCR kits kits -P ODING ETECTIONOF C .: 71-042 R ESPIRATORY HINO D &EV/C R EF ELL CONTROL ONTROL IAGNOSTIC HPRT1 G R C ON HINOVIRUS C ™™ AmplificationAmplification premix premix 15µL D UROPE NTEROVIRUS E HINO R 5’ N UPLEX 530530 nm nm SEIN D U ™ ELLULAR PathogenPathogen 1 1 ,C ARKINGIN ROTEIN MPV B E ROTEIN r-gene P H P OTFOR ODING FOR ODING FOR C C MPV: RSV: .N ONTROL H .: 71-041 R MPV ,CEM C H ENE EF ENE NLY SE UCLEUS ATRICIAL RSV A, RSV B R MPV A, U N O M H 15µL . 5560 nm 560 nm Cell control RSV/ athogen 2 ETECTIONOF NG MG Pa Pathogen 2 SE OC43) or C or Cell control D U EGATIVE . ™ 10µL 10µL ,N IAGNOSTIC B B: XTRACTION A: A/ AMPLES r-gene D ROTEIN ROTEIN E S ESEARCH P P R ODING FOR ODING FOR ONTROL ,G) A/B C C . F,G) C ITRO Extraction Extraction OR V .: 71-040 R AFTER NFLUENZA ENE ENE EF NFLUENZA I NFLUENZA N NFLUENZA I ESTS I I ATRICIAL ATRICIAL I R olol G 1,2,3,4) rrolrrol M M (1,2,3,4) ( ttrttr Amplification premix 15µL Amplification premix OSITIVE ESPIRATORY MG M OR nn NFLUENZA I R P 1H30 60 T -18°/-22°C. F USA:F 530530 nm nm onon r eer ITSFORTHE tte PathogenPathogen 1 1 a ARAMETERS: ee Co Co K ve Co Co vve vve iviv PARAMETERS: EST WaterWWa titi T aa ESTS T NCLUDED I ATHOGENS ydophila pneumoniae Négative Control Négative NégNég ITHIN P
ARGET W
T
TORAGE PRINCIPLE PRINCIPLE S
ENE
UMBEROF ESIGNATION ETECTED ONTROLS IT TATUS ESULT PECIMEN RINCIPLE OF THE ECHNOLOGY InfluenzaInfluenza A A Coronavirus (229E, NL63, HKU1, OC43) Parainfluenzavirus Coronavirus (229E, NL63, HKU1, O Parainfluenzavirus Cell Control Rhinovirus (A,B,C) Adenovirus (A,B,C,D,E,F,G) Cell Control Rhinovirus (A,B,C) Adenovirus (A,B,C,D,E,F Chlam Mycoplasma pneumoniae Legionella pneumophila Chlamydophila pneumoniae Chlamydophila Mycoplasma pneumoniae Legionella pneumophila Enterovirus (A,B,C,D) Bocavirus (1,2,3,4) Respiratory Syncytial Virus (A,B) Metapneumovirus (A,B) Influenza B Enterovirus (A,B,C,D) Bocavirus (1,2,3,4) Influenza B Respiratory Syncytial Virus (A,B) Metapneumovirus (A,B) ANGEOF S C R N K D S T G D P
ss s s s s s s s s s s s s s s s s s s s DETECTEDDETECTED PARAMETERS: P RESPIRATORY M.W.S. r-gene™ R s Respiratory M.W.S. r-gene
Respiratory M.W.S. r-gene Respiratory M.W.S. r-gene END-POINTPCR .HBIOEL EETO PROCEDURE DETECTION HYBRIDOWELL™ 3. AMPLIFICATION CONSENSUS 2. kits DNA 1. Biology Molecular PCR End-Point of Principle 20 S F S C U R R S LEXIBLE IAL FOR UITABLE IMPLE APID ESULTS TANDARDIZED OMPLETE SER -F : : RIENDLY I M EIA R S : V EADY BASED ILICA ALIDATION K IT : A : : OR UTOMATION - L ISFLO H AEPROCESS SAME THE FOLLOW KITS ALL ETHODOLOGY TO : N ISOLATION RNA -U SE : EAUAINCOATING DENATURATION RT AND 9 W (96 / OR YRDWL™D HYBRIDOWELL™ A S - A - M - P S R S R DATGS- ADVANTAGES - SLSWITHIN ESULTS EADY TANDARD OSITIVE IMILAR LL IAL FOR UITABLE oligonucleotide A LL ANY biotinylated ELLS R mlfe rdc analysis product Amplified AET RVDDI THE IN PROVIDED EAGENTS K MPLIFICATION - probe TO T ARE ITS P N , P OSSIBLE -U HYBRIDIZATION OESN FOR ROCESSING ) M GTV AND EGATIVE SE OLECULAR WITH A S O R ALOR MALL ALBEWITH VAILABLE EAGENTS NE B REAKS conjugate D ETECTION AY I B . THE E B . REACKABLE .: IOLOGY ( L I C ; A NHIBITION DETECTION BEFORE I ARGE P CUE IN NCLUDED P FOR LL STV AND OSITIVE OLORED REMIX K RWITHOUT OR S S ITS P P K TEP M AMPLE RAFTER OR OSITIVE IT substrate STV AND OSITIVE . ATERIALS . C ( substrate colorless P FROM NRL R NLDDIN INCLUDED ARE ONTROLS ROBES A S DETECTION ERIES S LL I NHIBITION S1C HSV1 E E TRIPS E N , lost ifrnit oiiesml rmpstv control. positive from sample positive differenciate to allows XTRACTION XTRACTION REEM ARGENE . product TATO TO XTRACTION colored F ; LNN VECTOR CLONING O h s fHV1o ABAseii probe specific LAMBDA or HSV-1 of use The HSV-1 HSV-1 REE S PECIAL dnia ETHadG % GC and LENTGH Identical C ONTROL C I pia Density Optical OC OF HOICE LAMBDA A , NHIBITION NRL OLWTHE FOLLOW ONTROLS HSV-1 K * READING IT O VIAL SSPRT REAGENTS SEPARATE AS AVAILABLE NOT PIIAINOR MPLIFICATION OLECULAR E (R UPETIS QUIPMENT D EF ETECTION :67-XXXBC). .: HSV-1 HSV-1 M E + ICROPLATE ACH V C ). IROLOGY MLFE FRAGMENT AMPLIFIED CONTROL POSITIVE HSV-1 S- MLFE FRAGMENT AMPLIFIED HSV-1 K ONTROLS IT N D . EEDED ETECTION M S AP AME . A . SSAYS P S RINCIPLE TEPS *, ). : END-POINTPCR 21 67-012 . . HYBRIDOWELL™ UBSTRATE NQUIRE I 96tests 67-012 LEASE + TMB S -P PRODUCTINFORMATION UROPE E ONJUGATE C : LATE . P ARKINGIN ROBE DNA. P EROXYDASE -P RAGMENT ). ,CEM . ICROTITER SE MPLIFIED M U A . ENSITY DNAF IOTINYLATED D TREPTAVIDIN B S EADER . UANTITATIVE R Q PTICAL IAGNOSTIC adapted probes are available in our catalog. For MPLIFIED D A LATE ETECTIONOF (O P ONTROL D KB C ETHODOLOGYON . ITRO Universal 67-012 1 NITS V ETECTIONWITH N ESTS I TO ICROTITER UALITATIVEOR YBRIDIZATIONUSING EGATIVE ™ NIVERSAL OR H 0.1 +2°C/+8°C. M F U ELISAM –> D N 3 H. 25. Q O.D.U 96 T HYBRIDOWELL™ NIVERSAL Universal Assay ™ EST T ESTS NITS QUIPMENT T Universal detection of amplified DNA on microwell plates. NCLUDED E U I ITHIN HYBRIDOWELL™ Universal - Complete kit W •
TORAGE
S
UMBEROF ECESSARY
IT ONTROLS TATUS EPORTING PECIMEN ESULTS ESULTS RINCIPLEOFTHE ECHNOLOGY R S T N C P R N R K S USEFOR HYBRIDOWELL™ U This kit containson all microwell necessary plates. reagents Amplified for the fragment analysis is of 96 directly amplified coated products on by the hybridization plate with then biotinylated hybridized probes with the biotinylated probe.
HYBRIDOWELL HYBRIDOWELL Hybrids areTMB. detected For with some a pathogenic streptavidin agents, peroxidase conjugate and detected with hydrogen peroxide associated with usage in your own systems, use probes biotinylated in 5’ during synthesis. END-POINTPCR EPSCNESSGENERIC CONSENSUS HERPES 67-090 GENERIC CONSENSUS HERPES The Assay GENERIC CONSENSUS HERPES re odtrieteeatvrsivle.Teapiidproduct amplified The involved. virus the exact with the obtained determine to order eeto n yigo hs ia eoe n ol be could and the genomes with IDENTIFICATION detected samples viral Positive HERPES these pathologies. HYBRIDOWELL™ GENERIC of these CONSENSUS HERPES in typing and important detection and C ttso epsiu oiieo epsiu eaie(M,HV1 S-,VV B,HV6 ilb eemndb sn a the using kit: by second determined a be using will performed HHV-6) EBV, is VZV, obtained HSV-2, HSV-1, samples (CMV, positive negative of herpesvirus Identification or IDENTIFICATION probe. positive generic herpesvirus of status e fncsaycnrl ovldt h eut bandare obtained results the complete Optical The validate reader. to (TMB). peroxidase microplate a kits. controls the with streptavidine microtiter in nm necessary tetramethylbenzidine a a included 450 of on at hybridized with read 3,3',5,5' set is probes is performed product and re- density biotinylated is or amplified specific conjugate re-extraction Detection each for Herpesvirus case need plate. 6 the this without with In assay amplification. identification the for lsia igotcpoeue o hs iue,priual utrs r o dpe oms eta evu system nervous prognosis. central patient most improve to to adapted therapy not not reasons are antiviral do with these along attacks adapted cultures, and For system 1 of nervous determination, required). nervous Herpes particularly central initiation volumes Herpesvirus central during available. viruses, early precise of inoculum are produced and these an high agents signs treatments rapid for allow The major inhibitors, clinical antiviral could etiology. The the (many procedures specific are data, herpesvirus specimens some encephalitis. diagnostic precise although supportive herpesviruses necrosing the Classical of 6 high, of clinical 70% The still to differentiation other is 20 tears. clinical for and encephalitis allow for humor responsible rate are aqueous 2 Mortality (CSF), infections. fluids cerebrospinal IDENTIFICATION HERPES 22 S FOR USE S L K C T P G N R N R S R E T E L P M O MTOF IMIT ECHNOLOGY TATUS EPORTING ESULTS ESULTS PECIMEN THE OF RINCIPLE IT ONTROLS ECESSARY OF UMBER ENE EPSCNESSGENERIC CONSENSUS HERPES S YRDWL™HRE IDENTIFICATION HERPES HYBRIDOWELL™ TORAGE T ARGET • • W D EPSCNESSGNRC-Cmlt kit Complete - GENERIC CONSENSUS HERPES EPSCNESSGNRC-Amplification/Detection - GENERIC CONSENSUS HERPES ITHIN ETECTION I U E NCLUDED M,HV1 S-,VV B,HV6cnessamplification. consensus HHV-6 EBV, VZV, HSV-2, HSV-1, CMV, T QUIPMENT NITS ESTS K T I ( T e. 67-050 ref.: EST EPSCNESSGENERIC CONSENSUS HERPES isalwdtcino h otcmo epsgnms nbooia ape uhas such samples biological in genomes, herpes common most the of detection allow kits i ihtesm mlfe rdc.The product. amplified same the with kit ) i a efrhraaye through analyzed further be can kit i losteDAprfcto,apiiainaddtcino ape o hc the which for samples of detection and amplification purification, DNA the allows kit +2°C/+8°C -18°C/-22°C M,HV1 S-,VV B,HHV-6. EBV, VZV, HSV-2, HSV-1, CMV, P USA: F T +2°C/+8°C T 192 U O.D. Q D 1 I C 15 CMV: A CSF, G D HYBRIDOWELL™ E S B:15C C 1.5 C 1.5 15 HHV-6: EBV: C VZV: 1.5 C 15 HSV-2: HSV-1: B M N NHIBITION OR HERMOCYCLER IOPSY ND OF CREENING OSITIVE EGATIVE ENE ICROTITER UALITATIVE AY -P i ( kit I N FOR C , . C OINT ESTS QUEOUS V DN FOR ODING NITS UTANEOUS ITRO C e. 67-050 ref.: R i lo rapid allow kit C ONTROL i sue again used is kit ESEARCH . C ONTROL C.C PCR. P . ONTROL (O FOR FOR LATE D . M,HV1 S-,VV B,HHV-6 EBV, VZV, HSV-2, HSV-1, CMV, FOR IAGNOSTIC PTICAL H OPY OPY OPIES OPY OPIES OPIES R R UMOR . R S U EF EF ONSENSUS . N P DNA R EADER PECIMEN . SE EF :67-090C. .: 67-000. .: TCININ ETECTION /PCR /PCR /PCR /PCR /PCR /PCR :67-090B. .: O D T , ENSITY in ) NLY . EARS U LMRS FTHE OF OLYMERASE A,V BAL, , N . SE A OT EM CE , ). G , MPLIFICATION F M OR YNAECOLOGICAL EPSCNESSGENERIC CONSENSUS HERPES ESICULAR ICROTITER U RIGIN ARKING SE I N F D LUID Argene IAGNOSTIC P S LATE IX E U , UROPE V S IRUSES . RINE PECIMENS RDC INFORMATION PRODUCT EPSCNESSGENERIC CONSENSUS HERPES P S , ROCEDURES P - : BY ERUM LEASE 0smls67-090 samples 50 0smls67-090BC samples 50 E . ND P , YRDWL™HERPES HYBRIDOWELL™ -P LASMA . I NQUIRE OINT and S , PCR. . A FROM WAB HYBRIDOWELL™ 67-090 L ESION kit . END-POINTPCR and 23 kit and - 67-050 .: 67-090). EF
kit. RESULTS . (R IT - NQUIRE . I EBV HHV-6 . ) may be further analyzed 96tests 67-050 LEASE -P ROCEDURES P HERPESCONSENSUSGENERIC PRODUCTINFORMATION DENTIFICATION - I . VZV ref.: 67-090 UROPE E LATE P kit ( IAGNOSTIC ENOME D N Argene HERPES CONSENSUS GENERIC I SE - ARKINGIN U ICROTITER . OR M HERPESCONSENSUSGENERICK F HERPESCONSENSUSGENERIC IRUS ). ,CEM OT V SE .N RGENE U . A ACH NLY ENSITY E - D O ). This typing is performed by using the same amplified material /PCR /PCR /PCR /PCR /PCR /PCR ETECTIONIN ), is used again for the identification assay without the need for re- HSV-2 CMV SE EADER . U R OPIES OPIES OPY OPIES OPY OPY PTICAL IAGNOSTIC D LATE (O . P ONTROL ESEARCH ONTROLFOR HERPESCONSENSUSGENERIC C R . C ITRO kit in order to determine the exact virus involved. The amplified product ref.: 67-090 NITS V kit, no further amplification is required. The ref.: 67-090 FOR + N ESTS I kit ( HSV-1 kit allows the identification of the specific virus present in the positive samples kit ( DENTIFICATION ICROTITER UALITATIVE EGATIVE
AMPLESAMPLIFIEDWITH OSITIVE kits allow detection of Herpes simplex types 1 and 2 (HSV-1 and HSV-2), OR RESULTS HSV-1:HSV-2: 15 C 1.5VZV: C EBV:HHV-6: 15 1.5 C 1.5 C C CMV: 15 C +2°C/+8°C. M F USA: CMV, HSV-1, HSV-2,HYBRIDOWELL™ VZV, EBV, D HHV-6S G P 3 H. 25. Q O.D.U 96 T N kit allow rapid detection and typing of these viral genomes and could be important in HERPES Identification Assay ™ HYBRIDOWELL™ EST HERPESCONSENSUSGENERIC HERPES Identification 67-050 T detection procedure HHV specific probes HERPESCONSENSUSGENERIC HERPESCONSENSUSGENERIC ESTS NITS QUIPMENT T Identification of positive samples obtained with NCLUDED E U I ETECTION ™ ITHIN HYBRIDOWELL™ HERPES Identification (for 67-090) D W HYBRIDOWELL™ HERPES Identification • TORAGE
S HYBRIDOWELL™ HERPES Identification amplified product UMBEROF ECESSARY
IT ONTROLS TATUS EPORTING ESULTS ESULTS RINCIPLEOFTHE PECIMEN ECHNOLOGY IMITOF R S R N S P C L N R K T USEFOR Herpes Consensus Generic obtained with obtained with the
HYBRIDOWELL™ HERPESCytomegalovirus (CMV), Identificationagents Varicella of Zoster centralare Virus nervous available. (VZV), system Herpes Epstein-Barr infections.nervous 1 Mortality and Virus attacks 2 rate (EBV),determination, are do for and responsible encephalitis not along Herpes forpatient with is allow virus 20 still prognosis. other to 6 clinical 70% high, clinical Classical (HHV-6)system of although differentiation diagnostic supportive which necrosing specimens some procedures are encephalitis. data, specific of (inhibitions,HYBRIDOWELL™ all for could antiviral The the these major important HERPES allow clinical treatments viruses, precisethese Identification an inoculum signs particularly early herpesvirus produced pathologies. volumes). cultures, initiation during For etiology. Positive are central of these not The samples adapted adapted reasons rapid antiviral to detected most therapy and with central to nervous precise improve Herpesvirus HYBRIDOWELL™ HERPES I The
HYBRIDOWELL HW through obtained with extraction ormicrotiter re-amplification. plate. EachOptical Detection density amplified is is readare performed product at included 450 with is in nmnumber a the with hybridized of a kits streptavidine microplate tests (including with reader. per peroxidase positive 6 The series. complete conjugate controls). Herpesvirus set This and of specific kit necessary 3,3',5,5' allows controls biotinylated tetramethylbenzidine one to to validate probes identify (TMB). the results on up obtained to a 14 positive samples depending on the END-POINTPCR NEOIU CONSENSUS ENTEROVIRUS acnto.Dansso neoiu netosdn yvrlclueioainde o lo h eeto fall of detection the allow widespread not to climates, requires does due and temperate culture isolation clinically (inhibitors) also In cell culture neonates. have encountered by difficult kit). in but viral not The rarely often incubation. isolation this disease does is is by of meningitis, with febrile days which enterovirus of which done specimen A, and several CSF (recently detected agents Moreover disease group a infections 68-71 a pathologies not causal culture. from as are Coxsackievirus in Enterovirus enterovirus muco-cutaneous Poliomyelitis, and 23 grow associated of with particularly disorders, 29-33 and often Diagnosis serotypes, associated are 24-27, 22 respiratory are 11-21, vaccination. Enteroviruses Echovirus cardiopathic, 1-9, Polioviruses with genus, seasonally. Echovirus The occur B1-6, associated Parechovirus been infections the Coxsackievirus A24, in enterovirus A1-22, reclassified Coxsackievirus 1-3, CONSENSUS ENTEROVIRUS 67-080 Assay CONSENSUS ENTEROVIRUS CONSENSUS ENTEROVIRUS fatbceilteayadalw niiito fan of initiation an allows with and genome. obtained therapy. therapy with results the Correlated antiviral the kit. of validated appropriate the data, antibacterial in are region supportive of included CONSENSUS results clinical coding controls ENTEROVIRUS These other non inhibition with probe. and 5' amplified generic positive The the tube. enterovirus in reaction single the is HYBRIDOWELL™ one isolation, in RNA region serotypes After enterovirus detection. CONSENSUS genome ENTEROVIRUS enterovirus-specific A 24 S FOR USE K T C P G N S R R N L S R TION O I AT C I F I L P M ECHNOLOGY MTOF IMIT TATUS EPORTING ESULTS ESULTS PECIMEN THE OF RINCIPLE IT ONTROLS ECESSARY OF UMBER ENE S NEOIU CONSENSUS ENTEROVIRUS TORAGE T ARGET • W D NEOIU OSNU Amplification/Detection - CONSENSUS ENTEROVIRUS ITHIN ETECTION I U E NCLUDED neoiu osnu amplification. consensus Enterovirus T QUIPMENT NITS ESTS T /D EST eeto spromdwt biotinylated a with performed is detection N O I T C E T E losa meit discontinuation immediate an allows sa losaoese TPRfrall for RT-PCR step one a allows assay a endsge odtc h N eoeo l neoiu eoye nldn Poliovirus including serotypes enterovirus all of genome RNA the detect to designed been has K i losrpdadsensitive and rapid allows kit T I +2°C/+8°C P YRDWL™D HYBRIDOWELL™ F T -18°C/-22°C T 192 U O.D. Q D 1 I C 30 S CSF, N 5’ E D M R N P NHIBITION OR HERMOCYCLER OSITIVE EVERSE ND ALPEBRAL TCINOF ETECTION EGATIVE ICROTITER UALITATIVE AY -P I ON OPIES N . OINT ESTS TOOL V NITS T C ITRO C RANSCRIPTION C ODING ONTROL /PCR. . C C ONTROL PCR. P T , . ONTROL (O ONJUNCTIVA FOR LATE D . ENTEROVIRUS HROAT FOR IAGNOSTIC PTICAL R R . R EGION EF . R EADER . EF :67-080C. .: TCININ ETECTION S :67-080B. .: D PECIMENS C + ENSITY . S . PECIMEN U ONSENSUS SE EM CE , ). BY N , M M , E ASOPHARYNGEAL ND ICROTITER RIGIN ARKING YOCARDIAL -P A PIIAININ MPLIFICATION OINT P PCR. LATE E B UROPE IOPSY . S RDC INFORMATION PRODUCT ECRETIONS P , S 1 P - ERICARDIAL LEASE TEP 0smls67-080BC samples 50 . . I NQUIRE F LUID . . 700BC 67-080 END-POINTPCR 25 INHIBITION CONTROL 67-130 PCR. . + OINT -P NQUIRE I ND . E BK probe One reaction tube Viral DNA purification BY LEASE 67-130 30 samples 67-130BC 30 samples 67-130 BK + -P ROCEDURES BKV P PRODUCTINFORMATION . AND UROPE E LATE JCV P IAGNOSTIC RESULTS . D N I Amplified product analysis SE ARKINGIN U ICROTITER - OR JC M F - Urine - Serum - CSF MPLIFICATION ). ,CEM OT A Positive controls are included in the kit. SE ISCRIMINATIONOF .N U D JC probe SAMPLE:
. . . ENSITY NLY ,CSF. D O .: 67-130B. ETECTIONIN .: 67-000. .: 67-130C. EF SE . EADER R ONSENSUS EF . EF EGION U EGION R . R R /PCR. R R LASMA PTICAL /PCR. IAGNOSTIC FOR . D ,P FOR LATE FOR (O ONTROL OPIES OPY . P ETECTIONAND PCR.C ONTROL C . ESEARCH ONTROL D C NTIGEN R NTIGEN ITRO C ERUM 1C NITS V ESTS OINT . ,S FOR N I AY -P ICROTITER UALITATIVE ENOMIC EGATIVE RINE ND OSITIVE HERMOCYCLER OR NHIBITION HYBRIDOWELL™ D N P M BKV: U T F USA: E JCV: T A JCV: 10 C I 1 D Q O.D.U 192 T +2°C/+8°C G -18°C/-22°C BKV: T A +2°C/+8°C kit allows the simultaneous kit allows the detection and the EST T IT ESTS K NITS QUIPMENT T Consensus amplification and differentiation of JCV and BKV. NCLUDED E U I ETECTION ITHIN JC/BK CONSENSUS - Amplification/Detection JC/BK CONSENSUS - Complete kit D W ARGET • •
T TORAGE
JC/BKCONSENSUS S JC/BKCONSENSUS
ENE ECESSARY UMBEROF
IT ONTROLS TATUS ESULTS EPORTING ESULTS PECIMEN RINCIPLEOFTHE IMITOF ECHNOLOGY OMPLETE R S C K L R N N S G P T R USEFOR C The detection and(BKV) identification ofcerebrospinal JC genomes virus fluid (JCV)polyomaviridae (CSF). and JC BK inasymptomatic and virus BK viruseschildhood. urine, or belong occur family. topatients JCV the serum, with reactivationleukoencephalopathy is non plasma,detected specific Primo-infections in responsible (PML). immunocompromized in signswith In and CSF. for from thistransplanted BKV Severe case, progressive patients. nephropathies reactivationurine are JCV In and/or this can are serum. case multifocal for associated BKV be can be renal detected in or bone marrow
identification ofthe both therapy viruses andopportunistic the and prognosis infections.are consequently amplified orientation After helpsa in of one microtiter in extraction, these singlebiotinylated severe plate reaction JCV using probes. tubeand and and positive hybridization BKV Results detected controls are in with included validated two in specific via the kit. inhibition JC/BKCONSENSUS The
JC/BK CONSENSUS Assay JC/BKCONSENSUS END-POINTPCR al eeto fdsiiae dnvrsifcinadipoe the improves and treatment. infection under patients adenovirus of up dissiminated of follow detection early DNVRSCONSENSUS ADENOVIRUS The 67-065 Assay CONSENSUS ADENOVIRUS CONSENSUS ADENOVIRUS r essniieta h eoi eeto ytmue ihthe with used system detection genomic techniques the CONSENSUS than immunoenzyme culture, and sensitive ADENOVIRUS for like less especially methods biological agglutination, severe are adenovirus their species conventional to to 7 The The benign into immunofluorescence, be according patients. protocol. probes can divided letter) typing infection a immunocompromised (A, serotypes Specific the by Adenovirus 50 species followed following than properties. probe. adenovirus F) more 7 adenovirus adenovirus the and the generic (Human includes of E all allows group a typing D, the of detection (AdV) C, with ensure The B2, kit B1, tube. screening the The adenovirus with biotinylated the amplification provided of amplification. a single genomic with allows one screening and plate in DNA amplification and serotypes microtiter of stool a purification in consensus secretions, following hybridization (nasopharyngeal probe using samples biopsy) biological in genomes, C 26 S FOR USE L K T C S P G N R R N S R E T E L P M O MTOF IMIT ECHNOLOGY TATUS EPORTING ESULTS ESULTS PECIMEN THE OF RINCIPLE IT ONTROLS ECESSARY OF UMBER ENE DNVRSCONSENSUS ADENOVIRUS S TORAGE T ARGET • • W D DNVRSCNESS-Cmlt kit Complete - CONSENSUS ADENOVIRUS DNVRSCNESS-Amplification/Detection - CONSENSUS ADENOVIRUS ITHIN ETECTION I U E NCLUDED ua dnvrscnessamplification. consensus Adenovirus Human T QUIPMENT NITS ESTS K T I d d 1AVB d d d d F AdV E AdV D AdV C AdV B2 AdV B1 AdV A AdV T + EST extraction fsml spstv,promtetpn ihtesm mlfe product. amplified same the with typing the perform positive, is sample If DNA kit. - i lostedtcino adenovirus of detection the allows kit DNVRSCONSENSUS ADENOVIRUS amplification Consensus - +2°C/+8°C -18°C/-22°C P R F T +2°C/+8°C T 192 U O.D. Q D 1 I C 60-125 N G RNA VA E S M YRDWL™D HYBRIDOWELL™ N NHIBITION OR HERMOCYCLER ECTAL OSITIVE ND AND CREENING EGATIVE ASOPHARYNGEAL ICROTITER UALITATIVE AY -P I N . OINT ESTS S V NITS WAB ITRO C C ONTROL . OPIES C ENE ONTROL C.C PCR. - P . ONTROL (O S , FOR FOR LATE D . FOR . IAGNOSTIC MALL PTICAL T /PCR. PN OF YPING R R . R S EF EF ONSENSUS . R EADER . ECRETIONS EF :67-065C. .: 67-000. .: I losan allows TCININ ETECTION NTESTINE :67-065B. .: D eeto procedure detection - d eei probe generic AdV ENSITY . HYBRIDOWELL™ U A SE LL A B , N , EM CE , ). MPLIFICATION A IOPSY DENOVIRUS ASOPHARYNGEAL M - ICROTITER RIGIN ARKING S , TOOL . S P EISBY PECIES . LATE - + E UROPE S . WAB RDC INFORMATION PRODUCT ,O sample positive AdV E eeto control detection P - ND PHTALMOLOGIC Negative LEASE -P 0smls67-065 samples 50 0smls67-065BC samples 50 OINT - I NQUIRE PCR. . S AMPLE 67-065 U , RINE . END-POINTPCR and and 27 . AND Legionella 67-025 Legionella Chlamydophila Legionella EGIONELLA , . L , , NQUIRE I . Mycoplasma pneumoniae 67-025 50 samples 67-025BC 50 samples 67-025 LEASE + and -P ROCEDURES Chlamylege positive sample P Mycoplasma pneumoniae PRODUCTINFORMATION . Legionella pneumophila UROPE and . E + LATE . HLAMYDOPHILA PNEUMONIAE . P IAGNOSTIC C ENE . D Legionella G N /PCR. Chlamydophila pneumoniae I , EGION SPACER Chlamydophila pneumoniae /PCR. SE U Legionella OPIES ICROTITER MARKINGIN , + OR RNA M DHESION OPIES F MPLIFICATION Legionella ). ,CE OT A DENTIFICATION OF : OMP2 R : 50 C I SE Chlamylege .N U . : P1 A : 50 C generic probe HYBRIDOWELL™ . NLY ENSITY /PCR. detection procedure D O .: 67-025B. INTERGENIC ETECTIONIN . .: 67-000. .: 67-025C. EF SE . R . ONSENSUS EF EF OPIES U . R R . The amplified products are detected on a microtiter plate after ™D PTICAL IAGNOSTIC FOR . D FOR FOR MPLIFICATION AND (O ONTROL . : 5S-23S : 50 C PCR.C ONTROL - A C . ESEARCH ONTROL C assay uses a single tube format for genic amplification of R C ITRO simplifies the etiologic research of atypical pneumopathies. This sensitive Chlamydophila pneumoniae NITS V ESTS OINT . FOR N I -P AY Chlamydophila pneumoniae ICROTITERPLATEREADER YCOPLASMAPNEUMONIAE YCOPLASMAPNEUMONIAE UALITATIVE YCOPLASMAPNEUMONIAE EGATIVE Mycoplasma pneumoniæ HLAMYDOPHILAPNEUMONIAE HLAMYDOPHILAPNEUMONIAE ONSENSUS ESPIRATORYSAMPLES OSITIVE ND HERMOCYCLER OR EGIONELLA EGIONELLA NHIBITION N HYBRIDOWELL M T F USA: C M L R C M L I 1 D Q O.D.U 192 T +2°C/+8°C C M E P -18°C/-22°C +2°C/+8°C Consensus amplification CHLAMYLEGE CHLAMYLEGE - Mycoplasma pneumoniae are bacteria frequently found among the pathogenic agents responsible for atypical by amplification in respiratory specimens. DNA probe provided with the kit allows to precise a positive result obtained with the and extraction Chlamydophila pneumoniæ kit allows simultaneous screening and identification of EST T IT Legionella K ESTS NITS QUIPMENT , T Amplification and detection of NCLUDED E U I ETECTION ITHIN CHLAMYLEGE - Amplification/Detection CHLAMYLEGE - Complete kit D W • • ARGET
T TORAGE
CHLAMYLEGE S
ENE ECESSARY UMBEROF
IT ONTROLS TATUS ESULTS EPORTING ESULTS PECIMEN RINCIPLE OF THE IMITOF ECHNOLOGY OMPLETE R S N R R T C N G P L S K USEFOR C generic probe. The accuracy of the results is validated by the inhibition and the positive controls included with the kit. Legionella pneumophila possible. After DNA isolation, the MycoplasmaMycoplasma pneumoniae pneumoniae The CHLAMYLEGE Assay
CHLAMYLEGE CHLAMYLEGE hybridization with biotinylated probes which are generic and/or specific of each bacteria group. In addition, a specific technique makes simultaneous detection of pneumopathies. Theseeven atypical inantimicrobial pneumopathies hospitals. therapy.etiological represent Traditional They diagnostic. a techniques are strong The time use proportion (immunological of consuming (25 (longer to tests 50%) than or of 3 the culture) days) pneumopathies and are listed are not not suitable sensitive to enough guide to a get quick an accurate initial pneumoniae NOTES 28 TABLE OF CONTENTS 29 39 34 35 36 37 38 30 33 NDEX I LPHABETICAL A See ………………………………………………………………………… ………………………………………………………………………………… NTIBODIES A IMMUNOLOGY ……………………………………………………………………………………… ……………………………………………………………………………………………………………………… ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………………………………………………… ……………………………………………………………………………………………………………………………… Pool (AdV, IA,Pool IB, (AdV, PIV) IA,Adenovirus IB, PIV,Influenza RSV) A Influenza B RSV Metapneumovirus Parainfluenza CMV HSV VZV ………………………………………………………………………………………………………………………………… ONOCLONAL EAGENTS LIDES R M S Hepatitis Complete kits HCMV ppUL83 (pp65) I.F. Antigenemia Herpes Virus Antibodies Product Line CINAkit Respiratory Viruses Antibodies Product Line
PTIMIZED NCILLARY
ONTROL OMPLETEKITS
A C
VIRUS O
C Table of contents IMMUNOLOGY rvddi h i a iectpamcbackground. cytoplasmic give can kit the studied. in strain provided CMV the Important: of to compared regardless when kit samples 4 positive alone. in two cells monoclonal of a in number the higher risk. of mutation conditions. low one optimum 3 very double of at under is a mutation laboratory antigen false a the since by 2 of avoiding parts caused ensures recognized, be specific polymorphonuclear thus can blood and epitopes that peripheral monocytes, negatives and infected of leukocytes nuclei the 1 CINA CINAkit h piie ln fcoe ( clones of blend optimized The kit Complete ANTIGENEMIA RAPID (pp65) ppUL83 HCMV CINAkit obokedgnu nyai ciiy(eoiaeo laiepopaae,as etosasgiiatlvlo the of level significant a and used destroys blood diagnosis technique also only the any the as is that enables peripheral phosphatase), viremia show It than alkaline Immunofluorescence studies Herpesviridae. hours). infected advanta or period 2 notably. other different cellular multiple of longer with within patients on (peroxidase However has a of AIDS reactivity used. for (results used blend nuclei and activity evidence be cross This is be positive procedure can No recipients the enzymatic is also Antigenemia others shorter graft antigen. and virus in can in ppUL83 endogenous the although ppUL83 clearly earlier (it and/or from a infections block method, appears blood expressed uptake also to detection disseminated dissemination is peripheral Antigenemia represents HCMV It of born epitopes recommended and of ppUL83 up The leukocytes blood co-culture. infection, follow from by different post infection. following hour isolation two demonstrated systemic one HCMV monocytes, The within active and labels an cells fluid). infected leukocytes blend cerebro-spinal of nuclei This the polymorphonuclear in appears innoculum. which (pp65), C 30 S FOR USE FOR USE N S E S N S T R P K R N odt,n ako estvt a enrpre ihthis with reported been a has stains sensitivity it of since lack no interest date, of To the also / reach is not pool does ppUL83 sample anti the This if / even reading Improved / in expressed epitopes different labels pool antibody This / E T E L P M O ECHNOLOGY TATUS EPORTING THE ESULT OF ENSITIVITY PECIMEN PITOP THE OF RINCIPLE IT ECESSARY OF UMBER OF UMBER S TORAGE W T • • T I K ARGET ITHIN IAi opeektHM pL3(p5 ..Antigenemia I.F. (pp65) ppUL83 HCMV kit complete CINAkit IAi opeektHM pL3(p5 ..Antigenemia I.F. (pp65) ppUL83 HCMV kit complete CINAkit U E CVpU8 muoloecneAtgnmai or ietyo leukocytes. only). on use directly (research hours 2 Antigenorachia in ppUL83 HCMV Antigenemia immunofluorescence ppUL83 HCMV T P QUIPMENT NITS ESTS K ATIENTS eodr nioisohrta h one the than other antibodies secondary HCMV T I T EST T EST CVpU8 p6)RAPID (pp65) ppUL83 HCMV CINApool ges : 902:20T 200 19-0028: S:K USA: F C +2°C/+8°C. P 50 19-002: T 100 19-002: N H 2 96.4% P I D PP 902:10P 100 19-0028: C MMUNOFLUORESCENCE OR ERIPHERAL ODE YTOCENTRIFUGE TCINOF ETECTION ME OF UMBER L3( UL83 sseii o h nenlmti tutrlpoporti 56 D ppUL83 kDa 65-68 phosphoprotein structural matrix internal the for specific is ) OURS I N 902N 19-002 V IT VS ITRO . PP 19-0028 C B P 65). ULTURE LOOD OSITIVE D HCMV IAGNOSTIC (C OT ATIENTS CSF. , ESTS ESTS ATIENTS . YTOSPIN A C IS . IN LSFOR ELLS ALBEI THE IN VAILABLE . . R P . GSEE BY EGISTERED ERIPHERAL . U 2 SE CE , OR 2 X ,S 3, 10 AKN IN MARKING B 5 LOOD FDA HANDON USA. C ELLS . FOR . ). E I N UROPE V ITRO RDC INFORMATION PRODUCT -P D IAGNOSTIC LEASE 19-002 902/19-0028 / 19-002 0 et 19-002 tests 100 0 et 19-0028 tests 200 I NQUIRE U SE . . IMMUNOLOGY 31 4 mL 19-002J 250µL 11-002I 5x 110mL 19-002C 5x 110mL 19-002E 1x 60mL 19-002K 1x 4.5mL 11-002G 20x 45mL 19-002B ------for HCMV ppUL83 Antigenemia. powder - 4x1liter 33-011 specimen 2+/2- 5slides 40-022 Argene 2 + and Mg 2 Ancillary reagents for HCMV ppUL83 Antigenemia. PBS pH: 7.2 without Ca Rapid lysis solution for CINAkit 19-002 Fixative solution for CINAkit 19-002 Permeabilization solution for CINAkit 19-002 Mounting medium for CINAkit 19-002 Dextran 6% for CINAkit 19-002 Antibodies dilution buffer for CINApool 11-002 Control slide CYTOMEGALOVIRUS IEA-EA Evans blue 1% for CINApool 11-002 • • • • • • • • •
USEFOR
Reagents for HCMV ppUL83 (pp65) Antigenemia Reagents for HCMV ppUL83 (pp65) Reagents and complementary small material available through IMMUNOLOGY O
32 Para Ade Influ Influ R.S. hMP inf no en en V. in V i lu vi za za fe nf en ru B A c ec z s te t s i in i e PTIMIZED a n n d d u B f A f 3 r fe e e i a c a p p i v c c n z t z a a t t o e n t f e n e t i e n i d e e d e d e
c e u n n u l
p
t l
f p 3 d p t
t
f
e a
n a
a .
s
n
A
s d I
t
I
V
t p
t
p
i
.
i
e i .
I
e
p
p
p e e
. e
p V
n
.
u n P u n
c a
c
u
t
S i
t
i t t
o
o i
.
m o t
m
r
i r
s
r
e s
s R
n
p
p
e
p
G
e
G n
G
e
A
p i n
e
i
e n
t
i
V
t
t
c
u t
c
c
h
s
P
s
s i n
n
i t
n
m i p
o
t
i m t
m
r
a
M A a
A
e
A
e
i
e
w
h e
i
G
n
c
n
h
h
n
h i
n
t n i
t i
e
e
t t i d
i
m
t
i
s d s d n e s n t w e w t t w a n a A a i A w n w i d i d i n a d n i n i t h s h t t e e e E LOCNRLSLIDES. cytoplasmic CONTROL a ALSO show SEE antibodies those staining. viruses. 3 respiratory immunofluorescence, or type In Parainfluenzae other specific. Parainfluenza with antigen cross-reactivity are No virus HN antibodies and monoclonal HA-1 murine These nuclear a show SLIDES. nasopharyngeal antibodies CONTROL on ALSO SEE those HeLa). H292, Immunofluorescence A549, staining. (MRC-5, in immunofluorescence, culture cell used In infected allows on group. be or antibodies Adenovirus secretions can entire monoclonal the murine It of of detection pool the optimized This cytoplasmic a shows SLIDES. respiratory CONTROL antibody other ALSO this SEE with staining. or B immunofluorescence, A Influenza In influenza an with viruses. recognizes cross-reactivity antigen. antibody No specific group monoclonal virus murine This In viruses. SLIDES. cross respiratory CONTROL cytoplasmic No ALSO a other SEE both tested. and staining. shows subtypes variants nuclear B antibody A and this and Influenza group Influenza H3N2) immunofluorescence, kDa with all 60 H2N2, to a reactivity H1N1, common recognizes (H0N1, antibody nucleoprotein monoclonal specific murine This cellular the inhibits SLIDES. CONTROL also ALSO It SEE shows vitro. staining. antibody cytoplasmic this in immunofluorescence, RSV a high, ability cells In RSV. the exceptionally all sensitive by neutralizes caused on infect fusion It is specificity. to present antibody 100% RSV this protein its of of for fusion affinity responsible The is RSV and B). the & of (A F1 strains and subunits kDa) (70 kDa) F0 the (48 recognizes antibody monoclonal murine This cytoplasmic a shows antibody viruses. the B). respiratory and staining. A other cytoplasmic immunofluorescence, (types with a In reactivity metapneumovirus recognizes cross human No for antibody specific monoclonal antigen murine This EPRTR IUE A VIRUSES RESPIRATORY ANTI ANTI ANTI ANTI ANTI ANTI NLEZ A INFLUENZA NLEZ B INFLUENZA ADENOVIRUS REF REF REF REF REF REF . ..3 P.I.V. hMPV R.S.V. :17- .: 17- .: 17- .: 17- .: :17- .: :17- .: 035 030 042 270 020 038 F F F ITC ITC ITC o nvtodansi s,C akn nErp laeinquire. Please - Europe in marking CE use, diagnostic vitro in For F F F ITC ITC ITC S:Frrsac s ny o o s ndansi procedures. diagnostic in use for Not only. use research For USA:
Para Rap Influ Influ R.S. hMP inf id A en en V. in V i lu d za za fe nf en e B A c ec z n te t a o in in e v f d d 3 i e fe r c c u c i c e n t e s t e e l l f l l e i d s s n d
c C s s f
c
t t T e A t
I a
e
a e
c
C
F 5
i
i
d
l
n
t T
n C
l
4 I
s e
s
T
e
e
F
I H
9
u
d
s
d
F
d NTIBODIES
r
U t
B i
3
c
a
f
v
w H
w
i
A e a
i
a
b
n
o
7 l z
z i
i
a l r
t
e n
t
s
o
n
h n
z h
c
d
e
w
e
b
e
n
e
A
d
A
u
l
u w
e C
l i
l
l a
l t n
f n
A
f
T
s
u
h I s
i
l
i t
n t t
n
f
t
F
I
i
i
t
w
i
h
A
n
c .
a
G
n h
I
i
r
p
V
A n
t e . M r A h a u t l p o n S C l i P . P s o h u t u T A i r I t G R V i i t o p F w n r G ...3 P.I.V. AdV B I. A I. R.S.V hMPV . IMMUNOLOGY 33 Format 15' Intended Use INCUBATION 4 mL 4 Dropper-bottle 0.5 mL 0.5 Concentrated 0.5 mL 0.5 Concentrated 33-011buffer dilution & Washing ref.: 40-161 ref.: 40-111 ref.: UENZA,PARAINFLUENZA,RSVGROUPFITC 80 tests 80 650 tests 650 650 tests 650 4 x 1L x 4 Quantity Cata. No. Anti-ADENOVIRUS GROUP FITC Anti-INFLUENZA A GROUP FITC Anti-INFLUENZA B GROUP FITC Anti-PARAINFLUENZA 1 FITC Anti-PARAINFLUENZA 2 FITC Anti-PARAINFLUENZA 3 FITC Anti-PARAINFLUENZA GROUP FITC Anti-RSV GROUP FITC Anti-ADENOVIRUS, INFLUENZA, PARAINFLUENZA GROUP FITC Anti-ADENOVIRUS, INFL Anti-HUMAN METAPNEUMOVIRUS FITC FITC Mab FITC FITC Mab FITC FITC Mab - 80 tests - dropper-bottle - 4 mL Purified Mab Purified PBS 020 030 035 036 037 038 040 042 091 092 270 Product Name * * * ref.: 40-121 ref.: 40-061 ref.:
17- 17- 17- 17- 17- 17- 17- 17- 17- 17- 17- Mounting medium for IF for medium Mounting mL 15 33-041coverslips microscope Mount XXX XXX XXX
Cata. No.: 17- 11- 12- Cata.No. MabDescription #tests Quantity
Use the individual code of each specific respiratory virus antibody. Respiratory Virus Antibodies Product Line All Formats are available: Additional Components: * Ready-to-use antibody blends and typing reagents: Antigen Control Slides: IMMUNOLOGY Herpes Virus Antibodies Product Line Product Antibodies Virus Herpes 34 ANTI culture detection. culture ANTI Infected cell Infected I HCMV ppUL83 Antigenemia after 2 hours 2 after Antigenemia ppUL83 HCMV directly on peripheral blood leukocytes. blood peripheral on directly MMEDIATE HCMV Antigen detection in 24-48 h. 24-48 in detection Antigen HCMV HSV-1 culture from clinical specimens. clinical from culture HCMV CINA ANTI E ARLY KIT PP / CINA HCMV A UL83 ( NTIGEN (Early detection on detection (Early POOL culture detection culture ANTI MRC-5 cells). MRC-5 Infected cell Infected (I.E.A.) PP 65) VZV IMMUNOLOGY 35 For research use only. 330 tests 0.5 mL (20x) 11-002 Concentrated 0.5 ml (50x) 11-004 For in vitro diagnostic use, CE marking in Europe - Please inquire. For in vitro diagnostic use, CE marking in Europe - Please inquire. USA: For research use only. Not for use in diagnostic procedures. USA: For research use only. Not for use in diagnostic procedures. - Concentrated 0.5 ml (50x) 11-003 ) ) CINApool is specific for the internal matrix structural phosphoprotein 65-68 kDa ppUL83 (protein kinase, pp65 or : ges HCMV Antigen detection in 24-48 h culture from clinicalHCMV specimens. Antigen detection on frozen or dewaxed tissue sections.HCMV in vitro sensitivity determination to antiviral drugs. HCMV Antigen detection in 24-48 h culture from clinicalHCMV specimens. Antigen detection by direct immunofluorescence slide test. HCMV ppUL83 Antigenemia 2 hours directly on peripheralHCMV blood ppUL83 leukocytes. Antigenorachia (research use only). anti HCMV ppUL83 (pp65) CINApool & Secondary F(ab’)2 FITC 330 tests 0.5 mL (20x) 14-002 anti HCMV I.E.A purified anti HCMV I.E.A+E.A purified anti HCMV ppUL83 (pp65) CINApool purified secondary secondary antibodies other than the one recommended can give cytoplasmic background. • • • •
USE FOR USE FOR USE FOR USE FOR USE FOR USE FOR USE FOR / / This antibody pool labels different epitopes expressed in the nuclei of infected peripheral blood polymorphonuclear leukocytes and monocytes, and / Improved reading even if the sample does not reach the laboratory under optimum conditions. / This anti ppUL83 pool is also of interest since it stains a higher number of cells in positive samples when compared to a monoclonal alone.
This murine monoclonal antibody recognizes the Immediate Early non structural proteins 52, 72 and 86 kDa. The common epitope labelled is encoded by exon 2 of the Major Immediate Early gene. This antigen appears 2 hours after cell infection, entire HCMV reaches infection cycle. Suitable It for gives the EBV use a and in specific ADV. cultures nuclear intensity fluorescence. VZV, No HSV-2, cross-reactivity peak with HSV-1, at 48 hours and persists during the from blood urine, (Buffy amniotic coat), fluid BAL, and colon, CSF, in brain, immunohistochemistry nerve... kidney, on lung, liver, SEE ALSO CONTROL SLIDES page 39. Anti CMV Immediate Early Antigen
This pool of murine monoclonal antibodies improves the sensitivity of antigen detection in culture at 48 hours post infection and of direct immunofluorescence direct of and infection post hours 48 at culture in detection antigen of sensitivity the improves antibodies monoclonal murine of Early pool an This recognizes antibody second the infection, post h 2 detected be can which Antigen Early Immediate an recognizes antibody first The BAL. in test slide Antigen which can be 12 detected hours for Suitable post with Both give use infection. other antibodies No nuclear staining. Herpesviridae. cross-reactivity nerves... brain, colon, kidney, on liver, lung, and in fluid immunohistochemistry amniotic urine, BAL, CSF, coat), (Buffy blood from in cultures SEE ALSO CONTROL SLIDES page 39. Anti CMV pool I.E.A + E.A pk65), pk65), which appears in the nuclei of infected cells within one hour post infection, and represents uptake different from the viral inoculum. This epitopes blend labels two expressed in dissemination (It can also be used on cellular cerebro-spinal fluid). The HCMV isolation from leukocytes of peripheral blood and/or ppUL83 Antigenemia is the nuclei of evidence for an active systemic infection. The ppUL83 Antigenemia infected appears earlier and is positive for a longer period than viremia as demonstrated by peripheral co- blood culture. polymorphonuclear It is also leukocytes a clearly and shorter procedure recipients monocytes, (results and AIDS patients. within Immunofluorescence is 2 following the only hours). detection method It recommended, although blood enables others can be the used. However borne diagnosis show that any different technique used to block endogenous studies enzymatic activity (peroxidase and or alkaline phosphatase), also destroys a significant level of the ppUL83 follow up of HCMV disseminated infections antigen. No in cross-reactivity with other Herpesviridae. graft This blend has multiple advanta The optimized blend of murine clones (
Anti CMV ppUL83 (pp65) CINApool Herpes Virus Antibodies Product Line 1 specific two in mutation double a since recognized epitope the of one of mutation by caused be theoretically can that negatives false avoiding ensures thus parts of the antigen is at very low risk. 2 3 Important: SEE ALSO CONTROL SLIDES page 39. IMMUNOLOGY SEE ALSO CONTROL SLIDES page 39. page SLIDES CONTROL ALSO of detectionSEE rapid and early for also used be can It culture. sensitivity.cell of inoculation after good infection Herpes very a with lavages) broncho-alveolar and rashes conjunctive or vesicular samples, genital biopsies, (skin samples direct labels It (glycoprotein). antigen common 2 type HSV and 1 type HSV a recognizes antibody monoclonal murine This HSV-1+2 Anti 39. page SLIDES CONTROL ALSO SEE culture. cell infected on use 2. For type HSV for specific is antibody monoclonal murine This HSV-2 Anti ELISA. and EIA, IF, culture. cell infected on use For protein. cytoplasmic 39. 1 page type SLIDES HSV with CONTROL reacts ALSO SEE antibody monoclonal murine This Line Product HSV-1 Anti Antibodies Virus Herpes 36 USE FOR USE FOR USE FOR USE FOR USE FOR USE FOR USE FOR USE • • • • • anti HSV-1 + 2 purified 2 + HSV-1 anti purified HSV-2 anti purified HSV-1 anti anti HSV-1 + 2 FITC 2 + HSV-1 anti anti HSV-1 + 2 FITC 2 + HSV-1 anti Infected cell culture detection (from vesicles or bronchoalveolar lavage). (EIA). Research bronchoalveolar or vesicles (from detection culture cell membrane. Infected mucous or skin on detection immunofluorescence Rapid Immunofluorescence). EIA, blot, (Western Research detection. culture cell Infected Immunofluorescence). EIA, blot, (Western Research detection. culture cell Infected For in vitro diagnostic use, CE marking in Europe - Please inquire. Please - Europe in marking CE use, diagnostic vitro in For USA: For research use only. Not for use in diagnostic procedures. diagnostic in use for Not only. use research For USA: 5 et . L11-090 mL 7.5 tests 250 11-089 mL 7.5 tests 250 11-088 mL 7.5 tests 250 5 et . L12-090 mL 7.5 tests 250 80 tests 80 . L17-090 mL 2.5 For research use only. use research For For research use only. use research For IMMUNOLOGY 37 For research use only. For research use only. 80 tests dropper bottle 17-017 650 tests 0.5 mL (40x) 11-017 650 tests 0.5 mL (40x) 11-018 Rapid immunofluorescence detection (on vesicular orInfected conjunctive cell rash,culture skin detection biopsy). (Early detection onResearch MRC-5 cells). (Immunofluorescence, EIA). Rapid immunofluorescence detection (on vesicular orInfected conjunctive cell rash,culture skin detection biopsy). (Early detection onResearch MRC-5 cells). (Immunohistochemistry). anti VARICELLA ZOSTER VIRUS FITC anti VARICELLA ZOSTER VIRUS purified anti VARICELLA ZOSTER VIRUS purified • • •
USE FOR USE FOR USE FOR USE FOR USE FOR USE FOR
This murine monoclonal antibody is infectedspecific with vesicularfor VZV or conjunctiveand shows rash SEEaor skincytoplasmic ALSObiopsies. andCONTROL membrane staining.SLIDES For early page 39. detection of VZV in MRC-5 cells Anti VZV Thismurine monoclonal antibody is specific for VZV GP63 and shows Ina nuclear immunocompromisedstaining in infected cells. patientsNo cross-reactivity (AIDS,with disseminatedother orHerpesviridae. graftinfections recipients). and vesicles Varicella which is oftenZostermore efficientare Virusdifficult on (VZV)HSV to (10 distinguishandto 20 Herpestimes) and SEE thanareSimplex onsometimes ALSO VZV, it Virusis atypical.useful CONTROL(HSV) to Sincedifferenciate canthe SLIDESbeantiviral HSV responsiblefrom treatment VZV. page 39. withfor Zovirax®
Anti VZV Herpes Virus Antibodies Product Line PRODUCTLISTBY CATALOG NUMBER Product List by Catalog Number Catalog by List Product 38 12-035 anti INFLUENZA B GROUP FITC GROUP B INFLUENZA anti FITC GROUP A INFLUENZA 12-035 anti FITC GROUP ADENOVIRUS 12-030 anti purified PARA. INFLU., ADENO., 12-020 anti purified 2 + HSV-1 11-091 anti purified HSV-2 11-090 anti purified HSV-1 11-089 anti purified MUMPS 11-088 anti purified MEASLES 11-046 anti purified GROUP RSV 11-045 anti purified GROUP PARAINFLUENZA 11-042 anti purified 3 PARAINFLUENZA 11-040 anti purified 2 PARAINFLUENZA 11-038 anti purified 1 PARAINFLUENZA 11-037 anti purified GROUP B INFLUENZA 11-036 anti purified HAV 11-035 anti purified HAV 11-034 anti purified GROUP A INFLUENZA 11-033 anti purified GROUP ADENOVIRUS 11-030 anti purified VIRUS ZOSTER VARICELLA 11-020 anti purified VIRUS ZOSTER VARICELLA 11-018 anti purified I.E.A+E.A HCMV 11-017 anti purified I.E.A HCMV 11-004 anti 11-002 11-003 CINApool for 1% blue Evans 11-002I 11-002 CINApool for buffer dilution purified Antibodies CINApool (pp65) ppUL83 HCMV 11-002G anti 11-002 19-002 CINAkit - Complete kit kit Complete - CINAkit FITC METAPNEUMOVIRUS human 19-002 anti FITC RSV PARA., INFLU., ADENO., 17-270 anti FITC PARA. INFLU., ADENO., 17-092 anti FITC 2 + HSV-1 17-091 anti FITC GROUP RSV 17-090 anti FITC GROUP PARAINFLUENZA 17-042 anti FITC 3 PARAINFLUENZA 17-040 anti FITC 2 PARAINFLUENZA 17-038 anti FITC 1 PARAINFLUENZA 17-037 anti FITC GROUP B INFLUENZA 17-036 anti FITC GROUP A INFLUENZA 17-035 anti FITC GROUP ADENOVIRUS 17-030 anti FITC VIRUS ZOSTER VARICELLA 17-020 anti FITC F(ab’)2 Secondary & CINApool (pp65) ppUL83 HCMV 17-017 anti FITC 2 + HSV-1 14-002 anti FITC GROUP RSV 12-090 anti FITC GROUP PARAINFLUENZA 12-042 anti FITC 3 PARAINFLUENZA 12-040 anti 12-038 HCMV ppUL83 (pp65) I.F. Antigenemia I.F. (pp65) ppUL83 HCMV p.33 p.33 p.33 p.33 p.36 p.36 p.36 p.33 p.33 p.33 p.33 p.33 p.33 p.33 p.33 p.37 p.37 p.35 p.35 p.31 p.31 p.35 p.32 p.33 p.33 p.36 p.32 p.33 p.32 p.33 p.33 p.32 p.32 p.32 p.37 p.35 p.36 p.33 p.33 p.33 p.30 - - Concentrated Concentrated mL 0.5 / µg 250 mL 0.5 / µg 250 ------dropper bottle 80 tests 80 tests 80 bottle dropper tests 80 bottle dropper tests 80 botttle dropper - tests 80 - bottle tests 80 dropper - bottle tests 80 dropper - bottle tests 80 dropper - bottle tests 80 dropper - bottle tests 80 dropper - bottle tests 80 dropper - bottle tests 80 dropper - bottle dropper - bottle dropper ------0.5 mL (40x) 650 tests 650 tests 650 (40x) mL 0.5 (40x) mL 0.5 0.5 mL (40x) 650 tests 650 tests 650 tests 650 (40x) mL 0.5 tests 650 (40x) mL 0.5 (40x) mL 0.5 (40x) mL 0.5 tests 650 tests 650 tests 650 (40x) mL 0.5 tests 650 (40x) mL 0.5 tests 650 (40x) mL 0.5 tests 650 (40x) mL 0.5 (40x) mL 0.5 (40x) mL 0.5 tests 650 tests 650 tests 650 (40x) mL 0.5 tests 650 (40x) mL 0.5 (40x) mL 0.5 Concentrated (40x) mL 0.5 Concentrated (50x) mL 0.5 (50x) mL 0.5 tests 330 (20x) mL 0.5 0.5 mL (20x) 330 tests 330 tests 650 (20x) mL 0.5 tests 650 (40x) mL 0.5 (40x) mL 0.5 1 mL (20x) 650 tests 650 (20x) mL 1 7.5 mL 7.5 mL 7.5 mL 7.5 mL 4.5 2.5 mL 2.5 mL 7.5 • 250 µL 250 - = CE marking in Europe in marking CE = 100 tests 100 250 tests 250 tests 250 tests 250 250 tests 250 80 tests 80 1x - PRODUCTLISTBY CATALOG NUMBER 39 ------5x 5x 1x 20x Liquid Liquid Liquid Liquid Liquid Liquid Liquid 2+ / 2- 2+ / 2- 2+ / 2- 2+ / 2- 2+ / 2- 7+ / 7- 2+ / 2- 2+ / 2- 2+ / 2- 2+ / 2- 2+ / 2- 200tests 200 tests -- - 4 mL 1 mL 2 mL 1 mL 2 mL 1 mL 2 mL 45 mL 60 mL 110 mL 110 mL 5 Slides 96 tests 96 tests 30 samples 50 samples 50 samples 50 samples 50 samples 50 samples 50 samples 50 samples 30 samples 30 reactions 30 reactions 10 reactions 100 µL - - - - - p.25 p.15 p.17 p.17 p.21 p.27 p.27 p.23 p.26 p.26 p.24 p.22 p.22 p.25 p.30 Idem Liquid dropper bottle 15 mL Liquid Powder 4 x 1 liter 10 wells10 wells 100 slides 100 slides 500 tests Specimen 5 Slides Specimen 5 Slides Specimen 5 Slides PolyclonalPolyclonal Polyclonal 0.5 mL Polyclonal Polyclonal PolyclonalPolyclonal 0.5 mL CDC V5-003 5 Slides CDC V5-002 5 Slides CDC V4-004CDC V6-004CDC V7-003 5 Slides 5 Slides 5 Slides CDC V7-002 5 Slides VR733/VR734 5 Slides p.33 p.33 p.33 p.31 p.31 p.31 p.31 p.31 p.31 p.33 p.31 p.33 HCMV ppUL83 (pp65) I.F. Antigenemia
68-009 Bocavirus r-gene™ Positive control 67-130BC JC / BK CONSENSUS - Amplification68-006 / Detection Quanti FluA r-gene™ 68-008 Quanti HHV8 QS r-gene™ 67-09067-090BC HERPES CONSENSUS GENERIC - Complete HERPES kit CONSENSUS GENERIC67-130 - Amplification / Detection JC / BK CONSENSUS - Complete kit 67-06567-065BC ADENOVIRUS CONSENSUS - Complete ADENOVIRUS kit CONSENSUS - Amplification67-080BC / Detection ENTEROVIRUS CONSENSUS - Amplification / Detection 67-02567-025BC CHLAMYLEGE - Complete kit CHLAMYLEGE - Amplification67-050 / Detection HYBRIDOWELL™ HERPES Identification (for 67-090) 51-011 F(ab’)2 anti MOUSE65-001 IgG+IgM “human ads.” FITC UNG r-gene™ 67-012 HYBRIDOWELL™ Universal - Complete kit 50-021 anti50-022 MOUSE IgG+IgM “human ads.” PEROXIDASE anti51-010 MOUSE IgG+IgM “human ads.” PEROXIDASE F(ab’)2 anti MOUSE IgG+IgM “human ads.” FITC 50-010 anti50-011 MOUSE IgG+IgM “human ads.” FITC anti50-012 MOUSE IgG+IgM “human ads.” FITC anti MOUSE IgG+IgM “human ads.” FITC 40-111 Control slide PARAINFLUENZA40-121 3 Control slide RSV 40-161 Control slide PANEL ADV,IA,IB,VRS,P1,P2,P3 40-081 Control slide INFLUENZA40-091 B Control slide PARAINFLUENZA40-101-1 1 Control slide PARAINFLUENZA 2 40-041 Control slide VARICELLA40-061 - ZOSTER Control slide ADENOVIRUS40-071 Control slide INFLUENZA A 33-041 Mounting medium for40-017 immunofluorescence Control slide HERPES40-022 SIMPLEX TYPE 1 & 2 Control slide CYTOMEGALOVIRUS IEA-EA 31-030 “Kova glasstic slides”33-011 for antigenemia PBS pH: 7.2 without33-030 Ca2+ and Mg2+ Evans blue 1% 19-002J Mounting medium for CINAkit 19-00219-002K Dextran 6% for CINAkit 19-002 31-010 IF slides - Teflon coated - 6 mm wells 19-002B Rapid lysis solution for CINAkit 19-00219-002C Fixative solution for CINAkit 19-002 19-002E Permeabilization solution for CINAkit 19-002 19-0028 CINAkit19-0028US - CompleteCINAkit kitComplete kit HCMV ppUL83(pp65) I.F. Antigenemia = CE marking in Europe
Product List by Catalog Number • PRODUCTLISTBY CATALOG NUMBER Product List by Catalog Number Catalog by List Product 40 71-006 FLU A/B r-gene™ Primers/Probes r-gene™ A/B FLU 71-006 Primers/Probe r-gene™ Virus BK 71-005 Primers/Probe r-gene™ Virus JC 71-004 r-gene™Primers/Probes species Legionella 71-003 Primers/Probe r-gene™ pneumoniae Mycoplasma 71-002 Primers/Probe r-gene™ pneumoniae Chlamydophila 71-001 kit Quantification - R-gene™ HHV6,7,8 CMV kit Complete Quantification - R-gene™ HHV6,7,8 CMV 69-100B kit Quantification - R-gene™ Virus 69-100 BK kit Complete Quantification - R-gene™ Virus BK 69-013B 69-013 69-011B kit Quantification - R-gene™ 69-011 ADENOVIRUS kit Complete Quantification - R-gene™ ADENOVIRUS 69-010B kit PCR Real-Time - R-gene™ 69-010 ENTEROVIRUS kit Complete PCR Real-Time - R-gene™ ENTEROVIRUS 69-005B kit Quantification - R-gene™ VZV HSV2 69-005 HSV1 kit Complete Quantification - R-gene™ VZV HSV2 HSV1 69-004B kit Quantification - R-gene™ 69-004 CMV kit Complete Quantification - R-gene™ CMV 69-003B kit Quantification - R-gene™ 69-003 EBV kit Complete Quantification - R-gene™ EBV 69-002B 69-002 Panel QC Clear CMV 68-020 71-105 RICO Extra r-gene™ Extra RICO 71-105 r-gene™ COMPENSATION COLOUR 71-103 r-gene™ Extra DICO 71-101 r-gene™ Ampli DICO 71-100 r-gene™ HCoV/PIV r-gene™ 71-045 p. Chlamydophila/Mycoplasma 71-044 r-gene™ AdV/hBoV 71-043 r-gene™ Rhino&EV/Cc 71-042 r-gene™ RSV/hMPV 71-041 r-gene™ A/B Influenza 71-040 r-gene™ Parechovirus 71-020 r-gene™ VZV 71-017 r-gene™ HSV2 71-016 r-gene™ HSV1 71-015 Primers/Probes 71-012 r-gene™ Adenovirus 71-010 Primers/Probe r-gene™ Bocavirus 71-009 Primers/Probes r-gene™ A/B hMPV 71-008 Primers/Probes r-gene™ A/B RSV 71-007 69-100R8 HHV8 amplificatio premix amplificatio HHV8 69-100R8 premix amplification HHV7 69-100R7 premix amplification HHV6 69-100R6 Bordetella parapertussis Bordetella BORDETELLA BORDETELLA BORDETELLA R-gene™ - Real-Time PCR kit PCR Real-Time - R-gene™ kit Complete PCR Real-Time - R-gene™ r-gene™ 3 vials 3 p.13 p.13 p.15 p.11 p.11 p.10 p.10 p.12 p.12 p.16 p.16 p.16 p.16 p.19 p.19 p.19 p.19 p.19 p.19 p.11 p.11 p.14 p.14 p.14 p.14 p.4 p.4 p.6 p.6 p.8 p.8 p.5 p.5 p.7 p.7 p.9 p.9 p.9 2 calibration runs 3 x 60 µL 60 x 3 runs calibration 2 0 ecin - - reactions 100 µL 750 x 2 reactions 100 reactions 100 60 reactions 2 x 450 µL 450 x 2 µL 450 x 2 reactions 60 µL 450 x 2 reactions 60 reactions 60 60 reactions 2 x 450 µL 450 x 2 reactions 60 60 reactions 2 x 450 µL 450 x 2 µL 450 x 2 reactions 60 reactions 60 60 reactions 2 x 450 µL 450 x 2 µL 450 x 2 µL 450 x 2 reactions 60 reactions 60 reactions 60 60 reactions 2 x 450 µL 450 x 2 µL 450 x 2 µL 450 x 2 reactions 60 µL 450 x 2 reactions 60 reactions 60 reactions 60 60 reactions 2 x 450 µL 450 x 2 reactions 60 140 tests 140 tests 140 tests 180 tests 180 60 tests 60 tests 60 90 tests 90 tests 90 tests 90 tests 90 60 tests 60 tests 60 tests 60 tests 60 tests 60 tests 60 tests 60 20 tests 20 tests 20 tests 60 90 tests 90 tests 90 tests 90 tests 90 tests 90 tests 90 3 x 1 mL Freeze dried Freeze mL 1 x 3 • = CE marking in Europe in marking CE = PRODUCTLISTBY CATALOG NUMBER 41 60 tests 2 x 450 µL 100 reactions 2 x 750 µL p.15 p.15 A(M) Group & H1N1 2009 r-gene™ Influenza
71-106 CELL Control r-gene™ 71-300 = CE marking in Europe
Product List by Catalog Number • ALPHABETICAL INDEX C B A Index Alphabetical 42 anti ADENO., INFLU., PARA., RSV FITC RSV PARA., INFLU., ADENO., anti purified PARA. INFLU., ADENO., anti FITC PARA. INFLU., ADENO., anti purified GROUP ADENOVIRUS anti concentred FITC GROUP ADENOVIRUS anti FITC GROUP ADENOVIRUS anti anti CMV ppUL83 (pp65) CINApool purified CINApool (pp65) ppUL83 CMV anti FITC F(ab’)2 Secondary & CINApool (pp65) ppUL83 CMV anti purified I.E.A+E.A CMV anti purified I.E.A CMV anti Panel QC Clear CMV anti BK R-gene™ - Quantification kit Quantification - R-gene™ BK kit Complete Quantification - R-gene™ Virus BK CINAkit - Complete kit kit Complete - CINAkit kit Complete - CINAkit kit Complete - CINAkit Detection / Amplification - CHLAMYLEGE kit Complete - CHLAMYLEGE Primers/Probes r-gene™ pneumoniae Chlamydophila r-gene™ Chlamydophila/Mycoplasma r-gene™ Control CELL BORDETELLA BORDETELLA parapertussis Bordetella control Positive r-gene™ Bocavirus Probe / Primers r-gene™ Bocavirus Probe / Primers r-gene™ Virus BK CINApool for buffer dilution Antibodies Primers/Probes r-gene™ Adenovirus r-gene™ AdV/hBoV kit Quantification - R-gene™ ADENOVIRUS kit Complete Quantification - R-gene™ ADENOVIRUS Detection / Amplification - CONSENSUS ADENOVIRUS kit Complete - CONSENSUS ADENOVIRUS Control slide Control IEA-EA CMV slide Control slide Control r-gene™ Compensation COLOUR kit Quantification - R-gene™ CMV kit Complete Quantification - R-gene™ CMV kit Quantification - R-gene™ HHV6,7,8 CMV kit Complete Quantification - R-gene™ HHV6,7,8 CMV HERPES SIMPLEX TYPE 1 & 2 & 1 TYPE SIMPLEX HERPES ADENOVIRUS R-gene™ - Real-Time PCR kit PCR Real-Time - R-gene™ kit Complete PCR Real-Time - R-gene™ HCMV ppUL83 (pp65) I.F. Antigenemia Antigenemia I.F. (pp65) ppUL83 HCMV Antigenemia I.F. (pp65) ppUL83 HCMV Antigenemia I.F. (pp65) ppUL83 HCMV r-gene™ VR733/VR734 5 slides 5 VR733/VR734 Freeze dried 3 x 1 mL 1 x 3 dried Freeze CDC V5-002 5 slides 5 V5-002 CDC p.14 p.13 p.13 p.10 p.10 p.27 p.27 p.19 p.15 p.14 p.11 p.11 p.19 p.26 p.26 p.16 p.30 p.30 p.33 p.33 p.33 p.32 p.33 p.32 p.35 p.35 p.35 p.35 p.6 p.6 p.5 p.5 p.4 p.4 rpe ote8 et 17-092 17-091 tests 80 tests 80 bottle dropper 17-020 bottle dropper tests 80 bottle dropper . L(0)60tss11-091 11-020 tests 650 tests 650 (40x) mL 0.5 (40x) mL 0.5 . L(0)30tss11-002 14-002 tests 330 tests 11-004 330 11-003 (20x) mL 0.5 Concentrated (20x) mL 0.5 Concentrated (50x) mL 0.5 (50x) mL 0.5 ,m 4X 5Tss 12-020 650Tests (40X) 0,5mL 5 L10ratos71-106 reactions 100 µL 750 x 2 5 L6 ecin 71-012 reactions 60 µL 450 x 2 5 L6 ecin 71-009 71-005 reactions 60 reactions 60 µL 450 x 2 µL 450 x 2 71-010 reactions 60 µL 450 x 2 0µ airto us71-103 runs calibration 2 µL 60 x 3 5 slides 5 0 L1 ecin 68-009 reactions 10 µL 100 4,5mL • 0ratos71-001 reactions 60 0smls67-025BC 67-025 samples 50 samples 50 67-065BC 67-065 samples 50 samples 50 = CE marking in Europe in marking CE = 0 et 19-0028US tests 200 4 et 69-100B 69-100 tests 140 tests 140 0 et 19-0028 19-002 tests 200 tests 100 0tss71-044 tests 60 71-043 tests 60 0tss69-011B 69-011 tests 60 tests 60 0tss69-013B 69-013 tests 90 tests 90 0tss69-010B 69-010 tests 90 tests 90 0tss69-003B 69-003 tests 90 tests 90 +/2 40-017 2- / 2+ +/2 40-061 2- / 2+ il 68-020 vials 3 11-002G 40-022 ALPHABETICAL INDEX 43 33-030 11-002I - 5x 19-002C 1x 19-002K Liquid 51-010 Liquid 51-011 2+ / 2-2+ / 2- 40-071 2+ / 2- 40-081 2+ / 2-2+ / 2- 40-091 40-101-1 40-111 2+ / 2-2+ / 2- 40-121 40-041 7+ / 7- 40-161 80 tests 17-090 250Tests 11-089 60 tests20 tests 69-100R6 20 tests 69-100R7 69-100R8 90 tests90 tests 69-002 69-002B 60 tests 71-045 90 tests90 tests 69-005 69-005B 250 tests250 tests 11-088 250 tests 12-090 11-090 180 tests180 tests 69-004 69-004B 50 samples50 samples 67-090 67-090BC 50 samples 67-080BC 1 mL 2 mL 60mL 250µL 7.5mL 110mL 7.5 mL 7.5 mL 2.5 mL 7.5 mL 0.5 mL 5 slides 5 slides 5 slides 2 x 450 µL 60 reactions 71-006 2 x 450 µL 60 reactions 71-008 2 x 450 µL2 x 450 µL 60 reactions 71-015 60 reactions 71-016 2 x 750 µL2 x 750 µL 100 reactions 100 reactions 71-100 71-101 250 µg / 0.5 mL250 µg / 0.5 mL Concentrated Concentrated 11-033 11-034 - - p.8 p.8 p.9 p.9 p.7 p.7 p36 p.36 p.36 p.36 p.36 p.31 p.15 p.19 p.22 p.22 p.14 p.31 p.16 p.16 p.24 p.12 p.12 Idem Liquid Specimen Specimen Polyclonal Polyclonal CDC V7-002CDC V4-004 5 slides CDC V6-004 5 slides CDC V7-003CDC V5-003 5 slides 5 slides 5 slides PANEL ADV,IA,IB,VRS,P1,P2,P3 PARAINFLUENZA 1 PARAINFLUENZA 2 PARAINFLUENZA 3 RSV VARICELLA - ZOSTER INFLUENZA A INFLUENZA B
HSV1 r-gene™ HSV2 r-gene™ HSV1 HSV2 VZV R-gene™ - Quantification Complete kit HSV1 HSV2 VZV R-gene™ - Quantification kit HHV7 amplification premix HHV8 amplification premix hMPV A/B r-gene™ Primers / Probes HERPES CONSENSUS GENERIC - Complete kit HERPES CONSENSUS GENERIC - Amplification / Detection HHV6 amplification premix HCoV/PIV r-gene™ Fixative solution for CINAkit 19-002 FLU A/B r-gene™ Primers / Probes F(ab’)2 anti MOUSE IgG+IgM “human ads.” FITC F(ab’)2 anti MOUSE IgG+IgM “human ads.” FITC ENTEROVIRUS R-gene™ - Real-Time PCR kit Evans blue 1% Evans blue 1% for CINApool EBV R-gene™ - Quantification kit ENTEROVIRUS CONSENSUS - Amplification / Detection ENTEROVIRUS R-gene™ - Real-Time PCR Complete kit DICO Extra r-gene™ EBV R-gene™ - Quantification Complete kit Dextran 6% for CINAkit 19-002 DICO Ampli r-gene™ Control slide Control slide Control slide Control slide Control slide Control slide Control slide Control slide
anti - HSV-2 purified anti HSV-1 + 2 purified anti HSV-1 purified anti HSV-1 + 2 FITC anti HSV-1 + 2 FITC anti HAV purified anti HAV purified = CE marking in Europe
H F
E D
Alphabetical Index • ALPHABETICAL INDEX P M L K J I Index Alphabetical 44 anti MOUSE IgG+IgM “human ads.” FITC ads.” “human IgG+IgM MOUSE anti FITC ads.” “human IgG+IgM MOUSE anti purified MEASLES anti purified GROUP B INFLUENZA anti FITC GROUP B INFLUENZA anti FITC GROUP B INFLUENZA anti purified GROUP A INFLUENZA anti FITC GROUP A INFLUENZA anti FITC GROUP A INFLUENZA anti Permeabilization solution for ICNAkit 19-002 ICNAkit for solution Permeabilization purified 3 PARAINFLUENZA anti FITC 3 PARAINFLUENZA anti FITC 3 PARAINFLUENZA anti purified 2 PARAINFLUENZA anti FITC 2 PARAINFLUENZA anti purified 1 PARAINFLUENZA anti FITC 1 PARAINFLUENZA anti purified GROUP PARAINFLUENZA anti FITC GROUP PARAINFLUENZA anti FITC GROUP PARAINFLUENZA anti Primers/Probe r-gene™ pneumoniae Mycoplasma purified MUMPS anti PEROXIDASE ads.” “human IgG+IgM MOUSE anti PEROXIDASE ads.” “human IgG+IgM MOUSE anti FITC ads.” “human IgG+IgM MOUSE anti Legionella species r-gene™Primers/Probes r-gene™Primers/Probes species Legionella Influenza Mounting medium for CINAkit 19-002 CINAkit for medium Mounting immunofluorescence for medium Mounting antigenemia for slides” glasstic "Kova Probe / Primers r-gene™ Virus JC Detection / Amplification - CONSENSUS BK / JC kit Complete - CONSENSUS BK / JC r-gene™ A/B Influenza wells mm 6 - coated Teflon - slides IF kit Complete - Universal HYBRIDOWELL™ 67-090) (for Identification HERPES HYBRIDOWELL™ PBS pH: 7.2 without Ca2+ and Mg2+ and Ca2+ without 7.2 pH: PBS r-gene™ Parechovirus A(M) Group & H1N1 2009 r-gene™ 2009 H1N1 & Group A(M) Polyclonal Polyclonal Polyclonal Polyclonal Polyclonal 10 wells 100 slides 100 wells 10 slides 100 wells 10 Powder iuddoprbtl 5m 33-041 mL 15 bottle dropper Liquid p.15 p.31 p.11 p.25 p.25 p.19 p.21 p.23 p.11 p.33 p.32 p.33 p.33 p.32 p.33 p.31 p.33 p.32 p.33 p.33 p.33 p.33 p.33 p.33 p.33 p.33 - - rpe ote8 et 17-035 tests 80 17-030 bottle dropper tests 80 bottle dropper rpe ote8 et 17-038 tests 80 17-037 bottle dropper 17-036 tests 80 17-040 tests 80 bottle dropper tests 80 bottle dropper bottle dropper . L(0)60tss11-045 tests 650 (40x) mL 0.5 . L(0)60tss11-046 tests 650 (40x) mL 0.5 . L(0)60tss11-035 12-035 tests 650 11-030 tests 650 (40x) mL 0.5 12-030 tests 650 (40x) mL 0.5 tests 650 (40x) mL 0.5 (40x) mL 0.5 . L(0)60tss11-038 12-038 tests 650 11-037 tests 650 (40x) mL 0.5 11-036 tests 650 (40x) mL 0.5 11-040 tests 650 (40x) mL 0.5 tests 650 (40x) mL 0.5 (40x) mL 0.5 0ratos240L71-003 2x450µL reactions 60 5 L6 et 71-300 tests 60 µL 450 x 2 L(0)60tss12-040 tests 650 (20x) mL 1 5 L6 ecin 71-004 reactions 60 µL 450 x 2 2 x 1 liter 1 x 2 0.5 mL 0.5 110mL 2 mL 2 mL 1 2 mL 2 mL 1 • 0ratos71-002 reactions 60 0smls67-130BC 67-130 samples 30 samples 30 = CE marking in Europe in marking CE = 0tss71-040 tests 60 6tss67-012 67-050 tests 96 tests 96 0tss71-020 tests 60 iud50-012 50-011 Liquid Liquid iud50-022 50-021 Liquid Liquid iud50-010 Liquid m 19-002J 4mL x19-002E 5x - - - 31-030 31-010 33-011 ALPHABETICAL INDEX 45 20x 19-002B 60 tests 71-042 60 tests 71-041 500 tests 65-001 30 reactions30 reactions 68-006 68-008 100 reactions 71-105 45mL 2 x 450 µL 60 reactions 71-007 2 x 450 µL 60 reactions 71-017 0.5 mL (40x)0.5 mL (40x) 650 tests 650 tests 12-042 11-042 0.5 mL (40x)0.5 mL (40x) 650 tests 650 tests 11-017 11-018 dropper bottle 80 tests 17-042 dropper bottle 80 tests 17-017 - p.9 p.33 p.32 p.33 p.37 p.37 p.37 p.15 p.17 p.31 p.19 p.16 p.14 p.19
VZV r-gene™ RSV/hMPV r-gene™ Rhino&EV/Cc r-gene™ RICO Extra r-gene™ RSV A/B r-gene™ Primers / Probes Quanti HHV8 QS r-gene™ Rapid Lysis solution for CINAkit 19-002 Quanti FluA r-gene™
anti VARICELLA ZOSTER VIRUS purified anti VARICELLA ZOSTER VIRUS purified anti VARICELLA ZOSTER VIRUS FITC UNG r-gene™ anti RSV GROUP FITC anti RSV GROUP FITC anti RSV GROUP purified = CE marking in Europe
V U
R Q
Alphabetical Index • NOTES
46 NOTES 47 NOTES 48
Photographer: Marc Mesplié E - M.BOURGEOIS PARIS. / E3 EXPANSION in France / Printed cations without notice / BIOMERIEUX, the blue logo are used, pending and/ used, / BIOMERIEUX, the blue logo are cations without notice
ARGENE S.A. 09340 Verniolle France Tel: +33 (0)5 61 69 61 00 Fax: +33 (0)5 61 69 61 01 bioMérieux S.A. 69280 Marcy l’Etoile France Tel: +33 (0)4 78 87 20 00 Fax: +33 (0)4 78 87 20 90 www.biomerieux.com www.argene.com www.biomerieux-diagnostics. com/argene 11-11 / 9302458/007/GB/A / This document is not legally binding. bioMérieux modify specifi reserves the right to document is not legally binding. This 11-11 / 9302458/007/GB/A 673 620 399 / bioMérieux to S.A. or one of its subsidiaries / RCS Lyon trademarks belonging ot registered Illustrations : ARGEN
couv_cata_2012_V22_ang.indd 2 9/12/11 11:19:23